

Evaluation of the bacteria detection capability of Microsart® ATMP Bacteria and Microsart® ATMP Sterile Release

| Product Identifier | |
|---------------------------|--|
| Version number | 1 |
| Release date | 25.09.2018 (ATMP Bacteria) 06.12.2019 (ATMP Sterile Release) |
| Document Identifier | |
| Version number | 2 |
| ID# | VA06.01EN |
| Release date | 06.12.2019 |
| Changes from last version | <ul style="list-style-type: none"> • ATMP Bacteria Extraction renamed to ATMP Extraction • ATMP Sterile Release includes the former ATMP Bacteria Patient with the addition of a PCR Kit the detection of fungal DNA • Minor revisions of text and data |
| Distribution | QM, R&D, Marketing |







| Approval | | | |
|------------------------|---|-------|------------|
| Test Facility 1 | Minerva Biolabs GmbH, Schkopauer Ring 12681 Berlin, Germany | | |
| Written by: |  Dr. Denis Ciato Head of Product Development | Date: | 07.02.2020 |
| Reviewed by: |  Matthias Hornschuh Scientist | Date: | 07.02.2020 |
| Reviewed by: |  Dr. Dirk Vollenbroich Managing Director | Date: | 07.02.2020 |
| Test Facility 2 | Sartorius Stedim Biotech GmbH, August-Spindler-Straße 11, 37079 Goettingen, Germany | | |
| Reviewed by: |  Dr. Diana Patzelt/Dr. Alexandra Mueller-Scholz Scientist Applications for Molecular Biology | Date: | 24.02.2020 |
| Reviewed by: |  Kai Nesemann Product Manger | Date: | 24.02.2020 |
| Reviewed by: |  Gerhard Haake/Anna Vreemann Quality Assurance Microbiology | Date: | 2020-02-24 |

Table of Contents

| | | |
|-----|--|-------------|
| 1 | Introduction..... | 1-3 |
| 2 | Objective | 2-4 |
| 3 | Definitions and Abbreviations | 3-5 |
| 4 | Responsibilities | 4-6 |
| 5 | Test Material..... | 5-7 |
| 5.1 | Test System | 5-7 |
| 5.2 | Sample Matrix | 5-7 |
| 5.3 | Microorganisms and ATMP samples for sensitivity, specificity and robustness testing | 5-8 |
| 5.4 | Incoming goods inspection and qualification of EZ-CFU | 5-9 |
| 5.5 | Compendial culture method | 5-11 |
| 5.6 | Equipment | 5-12 |
| 6 | Test Procedure..... | 6-14 |
| 6.1 | Sample preparation | 6-14 |
| 6.2 | Analytical procedures | 6-14 |
| 6.3 | System suitability test criteria | 6-17 |
| 6.4 | Directives for action | 6-17 |
| 6.5 | Calculations | 6-17 |
| 6.6 | Reporting requirements | 6-17 |
| 6.7 | Overview of experimental settings | 6-18 |
| | 6.7.1 LOD ₉₅ determination / Bacteria Detection Range | 6-18 |
| | 6.7.2 Specificity of PCR and bacteria detection range | 6-19 |
| | 6.7.3 Comparison of Microsart® ATMP Bacteria with compendial sterility test | 6-19 |
| | 6.7.4 Robustness | 6-20 |
| 7 | Study Results | 7-20 |
| 7.1 | LOD₉₅ Detection Limit | 7-21 |
| 7.2 | Specificity | 7-26 |
| | 7.2.1 Sequence Alignment | 7-26 |
| | 7.2.2 Bacteria Detection Range | 7-27 |
| | 7.2.3 Sample Matrix effects / Cross reactivity | 7-27 |
| | 7.2.4 Specificity of PCR | 7-27 |
| | 7.2.5 Comparison of Microsart® ATMP Bacteria with the compendial culture method | 7-28 |
| 7.3 | Robustness | 7-29 |
| | 7.3.1 Cell culture samples spiked with bacteria | 7-29 |
| | 7.3.2 Device compatibility | 7-29 |
| | 7.3.2 Detection of Free-DNA | 7-32 |
| | 7.3.3 False positive rate | 7-34 |
| 8 | Conclusion | 8-35 |
| 9 | Reference Documents..... | 9-36 |
| 10 | Appendix | 10-37 |

1 Introduction

Gene therapy, somatic cell therapy and tissue engineered products are classified as so called Advanced Therapy Medicinal Products (ATMPs). In contrast to parenteral drug products, microbial safety at time of lot release cannot be guaranteed for the majority of ATMP products. Typical shelf-lives of less than 48 hours are in contrast to the current compendial microbiological control test which takes 7 to 14 days before a contamination can be ruled out with certainty. For ATMPs, microbial safety cannot be guaranteed at time of admission. Furthermore some cases of microbial contamination have been reported for “aseptic” procurement, representing a relevant contamination burden for the process [1]. These facts explain the high demand for growth-independent rapid ATMP testing. In order to enhance sensitivity and duration of bacterial detection control tests, a more rapid method using real time PCR has been developed by the cooperation partners Minerva Biolabs and Sartorius Stedim Biotech. In this study, the kits Microsart® ATMP Bacteria and the Bacteria SR Mix from Microsart® ATMP Sterile Release were validated for the detection of bacterial contamination in ATMPs. The detection efficacy and efficiency of fungal DNA of Microsart® ATMP Sterile Release is not included in this report as being part of the Validation Report of Microsart® ATMP Fungi. Microsart® ATMP Bacteria as well as Bacteria SR Mix PCR include a mix of primer, nucleotides and polymerase containing a FAM™ labeled probe specific for a broad range of different bacterial genera. False negative results due to PCR inhibitors or improper DNA extraction are detected by the internal amplification control. The internal amplification control can be added to the sample prior to DNA extraction and analysis for verification of the complete process (DNA extraction and PCR reaction). The internal amplification control can also be added directly to the PCR master mix to act as a PCR control only. The amplification of the control reaction is detected at 610 nm (ROX™ channel) and the bacteria specific sequence at 520 nm (FAM™ channel).

2 Objective

A study was designed to evaluate the bacterial detection capability for the bacterial control detection Kits Microsart[®] ATMP Bacteria and the Bacteria SR Mix of its derivate product Microsart[®] ATMP Sterile Release, for qPCR. A number of guidance documents are published to demonstrate that rapid and alternative microbiological methods are suitable for their intended use. These include the Parenteral Drug Association (PDA) Technical Report 33, European Pharmacopoeia (Ph. Eur.) chapter 5.1.6 [2] and United States Pharmacopoeia (USP) chapter <1223> [3]. This comprehensive validation plan is intended to show suitability of the new products, Microsart[®] ATMP Bacteria and Microsart[®] ATMP Sterile Release, for bacterial control testing in ATMPs. The validation study was setup to fulfill Ph. Eur. chapter 5.1.6. Part 4-1-1, *Primary validation* to be performed by the supplier. Furthermore, recommendations of the Paul Ehrlich Institute have been implemented in the validation plan to fulfill the expectations of the German federal institute for vaccines and biomedicines [4] as well as the European Pharmacopoeia chapter 2.6.27 regarding the *Microbiological examination of cell-based preparations* [5]. All parameters were validated with characteristic and most challenging test setups. Furthermore, comparability to the compendial method was demonstrated. Selected spiked samples of the sensitivity testing (chapter 7.2) was tested in parallel at an external contract lab according to Ph. Eur. 2.6.1.

3 Definitions and Abbreviations

| | |
|--------------|--|
| ATMP | Advanced Therapy Medicinal Product |
| CFU/ml | Colony-forming Units per milliliter |
| DMEM | Dulbecco´s modified Eagles medium |
| DNA | deoxyribonucleic acid |
| EP/ Ph. Eur. | European Pharmacopoeia |
| FBS | Fetal Bovine Serum |
| GC/ml | genome copies per milliliter |
| L+S | Labor LS SE & Co. KG Mangelsfeld 4, 5, 6 97 708 Bad Bocklet Deutschland |
| LOD | limit of detection |
| MB | Minerva Biolabs GmbH |
| N/A | not applicable |
| NEC | negative extraction control |
| nm | nanometer |
| NTC | no template control |
| PC | positive control |
| PCR | polymerase chain reaction |
| PDA | Parenteral Drug Association |
| QC | Quality Control |
| SSB | Sartorius Stedim Biotech GmbH |

4 Responsibilities


Sartorius Stedim Biotech GmbH (SSB) was responsible for developing the test protocol in agreement with Minerva Biolabs GmbH (MB). MB was responsible for reviewing the test protocol to ensure its accuracy, completeness and validity.

Test initiation was scheduled by MB and SSB after approval of the validation plan by signing and exchanging a copy of the plan cover page and the necessary material for testing have been exchanged and received.

SSB and MB technicians executed the test protocol. MB and SSB were responsible for the execution of dedicated parts of the protocol.

MB drafted the validation report and SSB reviewed and approved the document to ensure its validity. The report was closed by exchanging a signed copy of the report cover page.

Deviations, including test failures and protocol modifications which occurred during the execution of the test protocol had been discussed between MB and SSB.

| | | |
|--|--|--|
|  | Product Validation Report Microsart® ATMP Bacteria/ Microsart® ATMP Sterile Release | Dated: 04.12.2019 Document Version: 2 Document ID: VA06.01EN Page 7 of 40 |
|--|--|--|

5 Test Material

The tests were conducted using the following test system, product solutions and material.

5.1 Test System

The test system used for the detection of bacteria during this study was as follows:

Table 1. Test System Information

| System type | Catalogue No. | Supplied by | Storage Conditions | Lot No. |
|--|---------------|-------------|---------------------|---|
| Microsart® ATMP Bacteria (100 reactions) | SMB95-1008 | SSB/MB | +2 – +8 °C | 9516S1097 9516S2097 9516S1028 9516S2028 9516S2048 |
| Bacteria SR Mix of Microsart® ATMP Sterile Release (Former Microsart® ATMP Bacteria Patient) (10 patients) | SMB95-1007 | SSB/MB | +2 – +8 °C | 9516S1078 |
| Microsart® ATMP Extraction (Former Microsart® Bacteria Extraction) (50 extractions) | SMB95-2001 | SSB/MB | Ambient Temperature | 95261077 95261107 95261028 |


5.2 Sample Matrix

Sample matrix, with defined cell culture medium components (Table 2), were used for specificity testing, LOD (Limit of Detection) determination and robustness testing. For sensitivity testing, a panel of 12 different bacterial species were diluted in DMEM + 5%FBS to prepare dilution series. Furthermore to demonstrate specificity and robustness, at least four different cell culture samples with different culture media compositions were spiked with 99 CFU/ml of one of the bacterial species which was detected with the highest LOD₉₅ value during LOD₉₅ determination (selected from the five EP 2.6.1/EP 2.6.27 bacteria listed Table 13A).

All matrices have been heat-treated for 20 min at 95 °C to inactivate all containing DNases. The heat-treated suspensions were stored ≤ -18 °C and intensively vortexed after thawing for immediate use.

Table 2. Matrix Formulation

| Product Ingredient | Manufacturer/Source | Catalogue No. | Lot No. | Storage Conditions |
|---|---------------------|---------------|----------|--------------------|
| DMEM medium | Merck/Biochrom AG | FG 0415 | 0374E | +2 - +8 °C |
| DMEM w/o Na-Pyruvat mit stable Glutamin | Merck/Biochrom AG | FG0435 | 1014F | +2 - +8 °C |
| DMEM high Glucose, GlutaMAX | Gibco/Thermo Fisher | 10566016 | 1930187 | +2 - +8 °C |
| RPMI 1640 | Gibco/Thermo Fisher | A1049101 | 1941065 | +2 - +8 °C |
| RPMI 1640, GlutaMAX | Gibco/Thermo Fisher | 72400013 | 1912692 | +2 - +8 °C |
| MEM | Sigma Aldrich | M8167-500ml | RNBG1617 | +2 - +8 °C |
| MEM | Sigma Aldrich | M4655-500ml | RNBG5441 | +2 - +8 °C |
| KnockOut DMEM | Gibco/Thermo Fisher | 10829018 | 1904921 | +2 - +8 °C |
| DMEM/F-12 GlutaMAX | Gibco/Thermo Fisher | 10565018 | 1930078 | +2 - +8 °C |

| | | |
|--|--|--|
|  | Product Validation Report Microsart® ATMP Bacteria/ Microsart® ATMP Sterile Release | Dated: 04.12.2019 Document Version: 2 Document ID: VA06.01EN Page 8 of 40 |
|--|--|--|

| Product Ingredient | Manufacturer/Source | Catalogue No. | Lot No. | Storage Conditions |
|---|---------------------|----------------------|--------------------|--------------------|
| Opti-MEM Reduced Serum GlutaMAX | Gibco/Thermo Fisher | 51985026 | 1929010 | +2 - +8 °C |
| McCoy's 5A Medium | Gibco/Thermo Fisher | 16600082 | 1897165 | +2 - +8 °C |
| Leibovitz L-15 Medium | Gibco/Thermo Fisher | 11415064 | 1922999 | +2 - +8 °C |
| Chondrocyte Differentiation Medium | Sigma Aldrich | 411D-250 | 745 | +2 - +8 °C |
| Human Osteoblast Differentiation Medium | Sigma Aldrich | 417D-250 | 715 | +2 - +8 °C |
| Mesencult ACF Basal Medium | Sigma Aldrich | 05456 | 17H83230 | +2 - +8 °C |
| Mesencult ACF Basal Medium + Mesencult ACF Supplement | Sigma Aldrich | 05457 | 16K74902-4 | ≤ -18 °C |
| ChondroMAX Differentiation Medium | Sigma Aldrich | SCM123-100ml | SLBT3800 | ≤ -18 °C |
| StemPro Osteo/Chond Dif Basal + StemPro Chondrogenesis Supplement | Thermo Fisher | A1006901 A1006401 | 1941369 1933294 | 2-8°C ≤ -18 °C |
| StemPro Osteo/Chond Dif Basal + StemPro Osteogenesis Supplement | Thermo Fisher | A1006601 A1006901 | 1950435 1941369 | 2-8°C ≤ -18 °C |
| Fetal bovine serum (FBS) | Biochrom AG | S0615 | 0167F | ≤ -18 °C |

5.3 Microorganisms and ATMP samples for sensitivity, specificity and robustness testing

For sensitivity, specificity and robustness testing, 18 different microorganisms were used, selected according to recommendations found in literature [Montag et. al, 2009; Paul Ehrlich Institute – Statement, 2 June 2015]. For CFU-based tests, 12 quantified microorganisms with a defined cell count (EZ-CFU), originated from the company “microbiologics” were used. These microorganisms are listed in table 3.

Table 3. Bacterial species tested

| Species | Classification | Strain | Supplier | LOT-No. | Catalogue-No. |
|--|----------------|------------|-----------------|-------------------------------------|---------------|
| Species used for CFU-based analysis | | | | | |
| <i>Bacteroides vulgatus</i> | Gram neg. | ATCC 8482 | Microbiologics | 445-56-2 445-76 | 0445C |
| <i>Escherichia coli</i> | Gram neg. | ATCC 8739 | Microbiologics | 483-555-1 | 0483C |
| <i>Pseudomonas aeruginosa</i> ^{a,b} | Gram neg. | ATCC 9027 | Microbiologics | 484-824 484-890-1 | 0484C |
| <i>Pseudomonas protegens</i> | Gram neg. | ATCC 17386 | Microbiologics | 524-40-2 | 0524C |
| <i>Streptococcus pyogenes</i> ^b | Gram neg. | ATCC 19615 | Microbiologics | 385-127-2 385-156-1 | 0385C |
| <i>Bacillus cereus</i> | Gram pos. | ATCC 10876 | Microbiologics | 998-141-1 998-161 | 0998C |
| <i>Bacillus subtilis</i> subsp. <i>spizizenii</i> ^{a,b} | Gram pos. | ATCC 6633 | Microbiologics | 486-402-1 486-448-2 486-550 | 0486C |
| <i>Clostridium sporogenes</i> ^{a,b} | Gram pos. | ATCC 19404 | Microbiologics | 317-138-1 317-162-1 317-172-1 | 0317C |
| <i>Enterococcus faecalis</i> | Gram pos. | ATCC 29212 | Microbiologics | 366-249-1 | 0366C |
| <i>Kocuria rhizophila</i> | Gram pos. | ATCC 9341 | Microbiologics | 688-143-1 | 0688C |
| <i>Staphylococcus aureus</i> subsp. <i>aureus</i> ^{a,b} | Gram pos. | ATCC 6538 | Microbiologics | 485-374-1 485-374-2 485-413 | 0485C |
| <i>Staphylococcus epidermidis</i> | Gram pos. | ATCC 12228 | Microbiologics | 371-154-1 371-234 | 0371C |
| Species used for DNA-based analysis | | | | | |
| <i>Bacteroides fragilis</i> | Gram neg. | ATCC 25285 | Minerva Biolabs | - | - |
| <i>Enterobacter cloacae</i> supsp. <i>cloacae</i> | Gram neg. | ATCC 13047 | Minerva Biolabs | 2110300541065 | 2110-30054 |
| <i>Klebsiella pneumoniae</i> | Gram neg. | ATCC 13883 | Minerva Biolabs | 2132301041075 | 2132-30104 |
| <i>Serratia marcescens</i> | Gram neg. | ATCC 13880 | Minerva Biolabs | 2117301211065 | 2117-30121 |
| <i>Clostridium perfringens</i> | Gram pos. | ATCC 13124 | Minerva Biolabs | 2108007561065 | 2108-00756 |
| <i>Yersinia enterocolitica</i> | Gram neg. | ATCC 9610 | Minerva Biolabs | 2140047801075 | 2140-04780 |

^a EP 2.6.1 listed bacteria strains
^b EP 2.6.27 listed bacteria strains

Another 6 microorganisms were tested at DNA-level using lyophilized DNA preparations containing genomic DNA of the particular species (Table 3) provided by MB. Bacteria were cultivated under ATCC® described conditions followed by DNA extraction, quantification and lyophilisation. Briefly, 5-10 ml are inoculated with the respective species and incubated overnight. A main culture of 50-100 ml is inoculated from the overnight culture and incubated before harvest at late logarithmic phase. Bacteria are harvested by centrifugation at 4000 x g at 4-8°C and genomic DNA is extracted via column purification.

Bacteroides fragilis was ordered as “KWIK Stik” from Doenitz ProLab. 10 ml of TSB were inoculated and incubated under ATCC® described conditions for two days. Genomic DNA was extracted via column purification with subsequent alcohol precipitation.

Extracted DNA is analyzed using standardized methods in the following order: a. initial QC consists of partial sequencing and is accompanied by Nanodrop measurement, b. OD ratios between $OD_{260/280} = 1.8-2.0$ and $OD_{260/230} >1.5$ are allowed for further analysis and c. DNA concentration of intact DNA is subsequently determined via Qubit and d. Qubit based concentrations are used for genome copy number determination.

Cells samples for specificity and robustness testing consist of four different cell culture samples representing a broad spectrum of host species and applications (Table 4). Cell lines are cultivated according to ATCC® sub culturing guidelines. Cell counts and flask numbers are increased by passaging till reaching the required amount of cells. At the final passage cells are harvested and counted followed by low speed sedimentation at 950 x g and adjustment to 10^6 and 10^5 cells/ml in DMEM containing 5% FCS.


Table 4. Description of cell samples used as background for spiking experiments

| Cell Type | Origin/ATCC | Species | Media Composition |
|-----------|---------------------------------------|-------------------------------|-------------------|
| HeLa | Cervix, epithelial, ATCC® CCL-2™ | <i>Homo sapiens</i> | DMEM, 5% FBS |
| Vero | Kidney, epithelial, ATCC® CCL-81™ | <i>Cercopithecus aethiops</i> | DMEM, 5% FBS |
| CHO-K1 | Ovary, epithelial-like, ATCC® CCL-61™ | <i>Cricetulus griseus</i> | DMEM, 5% FBS |
| RK13 | Kidney, epithelial, ATCC® CCL-37™ | <i>Oryctolagus cuniculus</i> | DMEM, 5% FBS |

5.4 Incoming goods inspection and qualification of EZ-CFU

All EZ-CFU of species listed in Table 6 were tested in an incoming good inspection to confirm the stated cell count. Two pellets of EZ-CFU were rehydrated in 2 ml of rehydration buffer and diluted in a 1:10 dilution step in a standard phosphate buffer pH 7.2. At least three agar plates (TSA) were inoculated with 100 µl, incubated for 24 to 48 h and checked for colony formation. The incubation conditions for each microorganism are listed in Table 6.

C. sporogenes and *B. vulgatus* are fastidious anaerobes. Without the use of an anaerobic gas chamber these microorganisms do not grow on agar plates. For this reason a most probable number test have been implemented for those species. Two pellets of EZ-CFU were rehydrated in 2 ml of rehydration buffer and diluted according to their individual cell count in a standard phosphate

| | | |
|--|--|---|
|  | Product Validation Report Microsart® ATMP Bacteria/ Microsart® ATMP Sterile Release | Dated: 04.12.2019 Document Version: 2 Document ID: VA06.01EN Page 10 of 40 |
|--|--|---|

buffer, pH 7.2., 25 ml fluid thioglycolate medium were inoculated with different concentrations in the range of 100 to 0.125 CFU/ml and incubated at 37 °C under anaerobic conditions. After 14 days, the turbidity of the medium was examined.

Cell counts of all EZ-CFU were confirmed to be in the range of 10 to 100 CFU. Consequently all EZ-CFU fulfill the manufacturer's specification and are accepted for validation.

Table 5. Bacteria Cultivation Media and Phosphate Buffer Ingredients

| Medium | Manufacturer | Catalog No. | Lot No. |
|---|---------------|--------------|----------------------------|
| Tryptic soy agar (TSA) | Merck Germany | 1.05458.0500 | VM676858505 VM717058547 |
| Tryptic soy broth (TSB) | Merck Germany | 1.05459.0500 | - |
| Soybean casein digest broth media | Merck Germany | STBMTSB12DP | F7PA54851 |
| Fluid thioglycolate medium | VWR Germany | 301051ZA | 88458 |
| Clear thioglycolate medium | Merck germany | STBMCTM12DP | F7SA54849 |
| NaH ₂ PO ₄ x 2 H ₂ O | Merck Germany | 1.06345.5000 | K93435445341 |
| Na ₂ HPO ₄ x 7 H ₂ O | Merck Germany | 1.06574.1000 | AM0732274437 |

Table 6. Incubation Conditions for each bacterial species (EZ-CFU)


| Species | Strain | Atmosphere | Temperature |
|--|------------|------------|-------------|
| <i>Bacillus subtilis subsp. spizizenii</i> * | ATCC 6633 | aerobic | 30 °C |
| <i>Clostridium sporogenes</i> * | ATCC 19404 | anaerobic | 37 °C |
| <i>Pseudomonas aeruginosa</i> * | ATCC 9027 | aerobic | 37 °C |
| <i>Staphylococcus aureus subsp. aureus</i> * | ATCC 6538 | aerobic | 37 °C |
| <i>Bacteroides vulgatus</i> | ATCC 8482 | anaerobic | 37 °C |
| <i>Escherichia coli</i> | ATCC 8739 | aerobic | 37 °C |
| <i>Pseudomonas protegens</i> | ATCC 17386 | aerobic | 26 °C |
| <i>Streptococcus pyogenes</i> | ATCC 19615 | aerobic | 37 °C |
| <i>Bacillus cereus</i> | ATCC 10876 | aerobic | 30 °C |
| <i>Enterococcus faecalis</i> | ATCC 29212 | aerobic | 37 °C |
| <i>Kocuria rhizophila</i> | ATCC 9341 | aerobic | 30 °C |
| <i>Staphylococcus epidermidis</i> | ATCC 12228 | aerobic | 37 °C |

* EP 2.6.1 listed bacteria strains


EZ-CFU standards are cultivated in bacterial media and lyophilized in a stabilizing matrix. Both, cultivation media as well as lyophilization matrix are potential sources of free environmental or process derived bacterial DNA. In order to assess the ratio of specific vs. unspecific DNA in EZ-CFU standards, the following procedure was exemplarily performed for *B. subtilis*, *P. aeruginosa*, *S. aureus* and *E. coli*:

EZ-CFU were rehydrated in 2 ml of rehydration buffer, diluted 1:10 and 100 µl aliquots were separated into pellet and supernatant via centrifugation at 18.500 g for 5 minutes. Supernatant (containing free DNA) and pellet (containing intact bacteria) were processed in parallel using Microsart® ATMP Extraction (the product previously named Microsart® Bacteria Extraction corresponds to the exact same product). DNA extracts were quantified via Microsart® ATMP Bacteria or a specific qPCR detection system for the appropriate species, respectively. Microsart® ATMP Bacteria shows total intact bacteria as well as total free-DNA in supernatant, while specific qPCR performed with AquaScreen® shows specific bacterial DNA in pellet and supernatant. Finally, a ratio of specific vs. unspecific DNA is calculated.


Standard Curve Microsart® ATMP Bacteria




Standard Curve AquaScreen® E.coli



Extracts Microsart® ATMP Bacteria (E. coli)



Extracts AquaScreen® (E. coli)



| | Microsart® ATMP Bacteria | | AquaScreen® E.coli | | Ratio specific/unspecific |
|--------------------|--------------------------|---------|--------------------|---------|---------------------------|
| | GC/PCR | GC/ml | GC/PCR | GC/ml | |
| Pellet | 80,97 | 1619,30 | 79,49 | 1589,70 | 1,01 |
| Supernatant | 37,19 | 3718,75 | 35,94 | 3594,25 | 1,03 |

5.5 Compendial culture method

Bacteria listed in Table 7 were spiked in DMEM + 5 % FBS and cultivated in thioglycolate medium and Soya-bean casein medium (TSB) for 14 days according to the recommendation of the European Pharmacopoeia for compendial culture method described in EP 2.6.1.

Table 7. Incubation Conditions for each Bacterial Species

| Species | Strain | Atmosphere |
|-------------------------------|------------|------------|
| <i>Bacillus subtilis</i> | ATCC 6633 | aerobic |
| <i>Staphylococcus aureus</i> | ATCC 6538 | aerobic |
| <i>Clostridium sporogenes</i> | ATCC 19404 | anaerobic |
| <i>Pseudomonas aeruginosa</i> | ATCC 9027 | aerobic |
| <i>Streptococcus pyogenes</i> | ATCC 19615 | aerobic |
| <i>Pseudomonas protegens</i> | ATCC 17386 | aerobic |

5.6 Equipment


The following lab equipment was used for the study:

Table 8. Lab Equipment at MB

| Equipment | Equipment-ID | Manufacturer | Brand |
|---|--|--------------------------------|-----------------|
| qPCR cyclers | R 04 0843, ES72 | Corbett Research | RotorGene 6000 |
| qPCR cyclers | 275001289, ES12 | Applied BioSystems | ABI Prism 7500 |
| qPCR cyclers | Model 401513; Serial No DE00700786 | Agilent Technologies | Mx3005P |
| qPCR cyclers | CFX96 Optics Ser. No. 785BR11826; C1000 Cyclers Ser. No. CT015330 | Bio-Rad | CFX Touch |
| Pipettes for master mix setup 0.5-10 µl 10-100 µl 100-1000 µl | E03, M25061D E04, L10238D E05, O10885D | Eppendorf | Reference 2 |
| 10-300 µl 10-300 µl | E60, 15011121 E66, 15017290 | Sartorius | Biohit Picus |
| Pipettes for Sample Handling 0.2-10 µl 10-300 µl 50-1000 µl | E69, 15023351 E70, 16010674 E71, 16009571 | Sartorius | Biohit Picus |
| Pipettes for DNA Extraction 10-100µl 10-100µl 100-1000µl 100-1000µl | E88, L56940G E13, L10224D E89, M45254G E14, O10970D | Eppendorf | Reference 2 |
| Vortex | E29, VB4B016638 | VWR | N/A |
| Glove box | E68, 22160256 | GS Glovebox Systemtechnik GmbH | Glovebox P10RT2 |

Table 9. Lab Equipment at SSB

| Equipment | Equipment-ID | Manufacturer | Brand |
|---|--|--------------------------------|---------------------|
| qPCR cyclers | Serial No: CT021642 | Bio-Rad | CFX96 touch |
| Glovebox | 12810/12811/12816 | GS Glovebox Systemtechnik GmbH | Glovebox P10RT2 |
| Laminar Flow | Heraeus LaminAir HLB 2448 | Heraeus | LaminAir |
| Vortex | No 541-10000-00-0; Ser. No 020314813 | Heidolph | REAX top |
| Micro centrifuge | Model AL220VAC; SN 053164 | Roth | Rotilabo-Zentrifuge |
| Centrifuge | Order No. 75003280; Ser. No. 237292 | Heraeus Instruments | Biofuge pico |
| Pipettes DNA-free 0.5 – 10 µl 2 – 20 µl 20 – 200 µl 100 – 1000 µl | 16007668 16007703 16009618 16008275 | Sartorius | Tacta |
| Electronic Pipettes DNA-free 10 – 300 µl | 16005936 | Sartorius | Picus NxT |
| Pipettes 0.5 – 10 µl 2 – 20 µl 10 – 100 µl 20 – 200 µl | 16007685 16007711 16006996 16009619 | Sartorius | Tacta |

| | | |
|--|--|---|
|  | Product Validation Report Microsart® ATMP Bacteria/ Microsart® ATMP Sterile Release | Dated: 04.12.2019 Document Version: 2 Document ID: VA06.01EN Page 13 of 40 |
|--|--|---|

| Equipment | Equipment-ID | Manufacturer | Brand |
|---------------|--------------|--------------|-------|
| 100 – 1000 µl | 16008272 | | |

The following consumables were used:

Table 10. DNA-free lab ware used at MB

| Article no. | Article name | Manufacturer / Supplier |
|---|---|-------------------------|
| 72.706.400 72.991.103 70.1116.210 70.760.212 70.765.210 70.762.211 | Micro tubes, 1.5 ml, DNA-free PCR-tubes, Multiply-µStripPro Biosphere filter tips 0.5 – 20 µl Biosphere filter tips 2 – 100 µl Biosphere filter tips 20 – 300 µl Biosphere filter tips 100 – 1000 µl | Sarstedt |
| 710970X 710975X 711200 | PCR tubes, optical, DNA-free, high profile, SingleCap, 8er-SoftStrips 0.2 ml PCR tubes, optical, DNA-free, low profile, SingleCap, 8er-SoftStrips 0.2 ml PCR 0.1 ml 4-tubes & 4-Cap Strips | Biozym |

Table 11. DNA-free lab ware used at SSB

| Article no. | Article name | Manufacturer / Supplier |
|---|--|-------------------------|
| 72.991.103 70.1116.210 70.760.212 70.765.210 70.762.211 | PCR-tubes, Multiply-µStripPro Biosphere filter tips 0.5 – 20 µl Biosphere filter tips 2 – 100 µl Biosphere filter tips 20 – 300 µl Biosphere filter tips 100 – 1000 µl | Sarstedt |
| 710970X 710975X | PCR tubes, optical, DNA-free, high profile, SingleCap, 8er-SoftStrips 0.2 ml PCR tubes, optical, DNA-free, low profile, SingleCap, 8er-SoftStrips 0.2 ml | Biozym |

6 Test Procedure

Sample preparation prior testing is strictly required for highest confidence and sensitivity. The design and performance of pre-analytical procedures are part of this study in respect of the intended use but cannot reflect the diversity of the sample material in total. The templates for the PCR analysis are prepared by direct extraction of the sample and subsequent PCR analysis.

6.1 Sample preparation

Microsart® ATMP Extraction and Microsart® ATMP Sterile Release Kit are optimized to extract genomic bacterial DNA from different sample matrices including cell culture samples, reducing handling steps and thus contamination to a minimum. The Internal Control DNA of Microsart® ATMP Bacteria and Microsart® ATMP Sterile Release can be used to monitor the extraction process. Extraction of bacterial DNA was carried out according to the suitable instruction manual.

In detail:

1. Transfer 1 ml sample into a provided DNA-free 1.5 ml processing tube (transparent cap)
2. Centrifuge at 16200 x g for 15 minutes
3. Remove the supernatant carefully and completely

Attention: Samples can only be inactivated or frozen after this sample collection step.

4. Add 500 µl of Lysis Buffer to the sample

Optional: Add 20 µl Internal Control DNA from Microsart® ATMP Bacteria kit or from Microsart® ATMP Sterile Release kit to the sample to monitor the extraction process.

7. Vortex vigorously for 30 seconds until pellet is completely lysed
8. Heat at 80°C for 10 minutes
9. Spin down at 16200 x g for 10 minutes
10. Remove supernatant carefully and completely, do not withdraw the pellet
11. Add 100 µl Suspension Buffer (violet cap) and suspend pellet by vortexing

6.2 Analytical procedures

The detection of bacterial DNA will be carried out according to the instruction manual.

In detail:

Rehydration of the Reagents:

1. Centrifuge tubes with lyophilized components (5 sec at maximum speed)
 2. Add 390 µl (Microsart® ATMP Bacteria) of Rehydration Buffer to each Bacteria Mixes or 90 µl (Microsart® ATMP Sterile Release) of Rehydration Buffer to each Bacteria SR Mixes
 3. Add appropriate amount of deionized, DNA-free water
Positive Control DNA 300 µl
Internal Control DNA 800 µl
 4. Incubate for 5 minutes at room temperature
 5. Vortex and centrifuge again
-

PCR master mix setup:

Total volume per reaction is 25 µl including 10 µl of sample. When setting up reactions, calculations include positive (PC) and negative controls (NTC). Pipet master mix into a 1.5 ml reaction tube and mix gently.

Pipetting scheme Microsart® ATMP Bacteria:

| | for 1 reaction | for 26 reactions |
|----------------------|----------------|------------------|
| Bacteria Mix | 15 µl | 390.0 µl |
| Internal Control DNA | 1.0 µl | 26.0 µl |

Pipetting scheme Microsart® ATMP Sterile Release:

| | for 1 reaction | for 6 reactions |
|----------------------|----------------|-----------------|
| Bacteria SR Mix | 15 µl | 90.0 µl |
| Internal Control DNA | 1.0 µl | 6.0 µl |

Attention: If the Internal Control DNA was added to the sample during DNA extraction, add 15 µl of the Bacteria Mix or Bacteria SR Mix directly to each PCR tube.

Loading the test tubes:

Aliquot 15 µl of master mix into each PCR reaction tube. After pipetting the negative control (10 µl of water or elution buffer of DNA extraction kit), the tube must be sealed before proceeding with the samples. Add 10 µl of sample to each PCR reaction tube. Seal the tubes completely before proceeding with the positive control (10 µl) in order to avoid cross contamination.

Programming the qPCR cycler Rotorgene 6000 (5-plex):

Program Step 1: Pre-incubation

| | |
|------------------|-------------|
| Setting | Hold |
| Hold Temperature | 95°C |
| Hold Time | 3 min 0 sec |

Program Step 2: Amplification

| | |
|-----------------------|-----------------------|
| Setting | Cycling |
| Cycles | 40 |
| Denaturation | 95 °C for 30 sec |
| Annealing | 55 °C for 30 sec |
| Detection/ Elongation | 60 °C for 45 sec |
| Gain setting | automatic (auto gain) |
| Slope Correct | activated |
| Ignore First | deactivated |

Programming the qPCR cycler ABI Prism® 7500:

Program Step 1: Pre-incubation

| | |
|------------------|-------------|
| Setting | Hold |
| Hold Temperature | 95°C |
| Hold Time | 3 min 0 sec |

Program Step 2: Amplification

| | |
|-----------------------|------------------|
| Setting | Cycling |
| Cycles | 40 |
| Denaturation | 95 °C for 30 sec |
| Annealing | 55 °C for 30 sec |
| Detection/ Elongation | 60 °C for 45 sec |

Programming the qPCR cycler Mx3005p®:

| | |
|----------------------|---|
| Segment 1 (Pre-Melt) | 95°C, 3 min 0 sec |
| Segment 2 | 95 °C for 30 sec |
| | 55 °C for 30 sec |
| | 60 °C for 45 sec, data collection |
| Cycles | 40 |
| Analysis mode: | adaptive baseline (baseline correction) |

Programming the qPCR cycler CFX96 touch:

Program Step 1: Pre-incubation

| | |
|------------------|-------------|
| Setting | Hold |
| Hold Temperature | 95°C |
| Hold Time | 3 min 0 sec |

Program Step 2: Amplification

| | |
|-----------------------|--------------------------------|
| Setting | Cycling |
| Cycles | 40 |
| Denaturation | 95 °C for 30 sec |
| Annealing | 55 °C for 30 sec |
| Detection/ Elongation | 60 °C for 45 sec, all channels |

Result Interpretation:

The presence of bacteria in the sample is indicated by an increasing fluorescence signal in the bacterial FAM™ channel during PCR. In order to interpret results accurately, a baseline has to be set. This threshold was defined as 10% of the maximum fluorescence level of the positive control.


The presence of bacteria in the sample is indicated by an increasing fluorescence signal in the bacterial FAM™ channel during PCR.

Table 12. Result interpretation Microsart® ATMP Bacteria and Microsart® ATMP Sterile Release

| Detection of Bacteria FAM™ channel | Internal Control ROX™ channel | Interpretation |
|---------------------------------------|----------------------------------|-------------------|
| positive (C _q < 40) | irrelevant | Bacteria positive |
| negative (no C _q) | negative (no C _q) | PCR inhibition |
| negative (no C _q) | positive* | Bacteria negative |

*see chapter 6.3 for definition of positive

A successfully performed PCR without inhibition is indicated by an increasing fluorescence signal in the internal control channel. The provided Internal Control was added to the PCR master mix or as extraction control. Bacterial DNA and Internal Control DNA are competitors in PCR. Because of

| | | |
|---|--|---|
|  | Product Validation Report Microsart® ATMP Bacteria/ Microsart® ATMP Sterile Release | Dated: 04.12.2019 Document Version: 2 Document ID: VA06.01EN Page 17 of 40 |
|---|--|---|

the very low concentration of Internal Control in the PCR mix, the signal strength in this channel is reduced with increasing bacterial DNA loads in the sample.

6.3 System suitability test criteria

Internal control (ROX™) must show C_q-values in the range of +/- 2 cycles of the no-template control (master mix control) if used as PCR control. If the internal control is used as extraction control it must show C_q-values in the range of +/- 3 cycles of the no-template control (master mix control). To exclude contaminations, the extraction control and the master mix control (FAM™) must be negative (no C_q-value or C_q-value > 40). The PCR positive control must show C_q-values of 24 +/- 2 cycles (FAM™).

6.4 Directives for action

During specificity testing and LOD₉₅ determination (see Tables 13A and 14) 7 out of 8 NECs have to be negative. If more than one NEC is positive, PCR was repeated. If NEC is confirmed positive, extraction was repeated. In case of positive NTC, PCR was repeated.

For robustness testing (see Tables 17) two out of two NECs have to be negative. If NECs were positive, PCR was repeated. If NEC was confirmed positive, extraction was repeated. In case of positive NTC, PCR was repeated. Due to the environmental abundance of bacterial DNA it cannot be guaranteed that all cell culture samples used as spiking matrix are free of bacterial DNA. Thus, in case of a positive signal for NEC that was confirmed after re-testing, samples were send for sequencing and parallel sterility testing at an external contract lab in order to distinguish between true- and false-positive signal. This way the NEC of the different sample matrices also provides information regarding specificity. In addition, sequence alignments were done to get an impression of the broad bacteria detection capability of Microsart® ATMP Bacteria and Microsart® ATMP Sterile Release.

During LOD₉₅ determination for the Bacteria SR Mix of Microsart® ATMP Sterile Release (see Table 13B), 1 out of 2 NEC/NTC have to be negative. If more than one NEC/NTC is positive, PCR was repeated. If NEC/NTC is confirmed positive, extraction was repeated.

6.5 Calculations

N/A

6.6 Reporting requirements

The reports generated by the qPCR machine were printed in color. All run information were printed, including protocol, sample identification, internal amplification control curves (ROX™ filter) and target curves (FAM™ filter) and filed according to the chapter structure of this validation plan. Sample identification should contain information on the species, the contained concentration in CFU/ml or GC/ml or alternatively the type of control (PC for Positive Control, NC for Negative Control, NTC for No Template Control and NEC for Negative Extraction Control).

6.7 Overview of experimental settings

6.7.1 LOD₉₅ determination / Bacteria Detection Range

The experimental setup of each test is listed in the following tables. All tests of Table 13A were performed six times to have at least 24 results for each CFU concentration of each of the five bacterial species listed in EP 2.6.1 and EP 2.6.27 available as EZ-CFU, and 48 results for NEC.

Table 13A. Test setup for LOD₉₅ determination of bacterial species listed in EP 2.6.1 and EP 2.6.27

| Detection Limit | | | | | | | | |
|-----------------|---|---------------------------|---------------------------|---------------------------|--------------------------|----------------------------|-----------------------------|--------------------------|
| 1 | Spike DMEM + 5 % FBS with <i>Bacillus subtilis</i> | | | | | | | |
| | 99 CFU/ml → 4 aliquots | 50 CFU/ml → 4 aliquots | 25 CFU/ml → 4 aliquots | 10 CFU/ml → 4 aliquots | 5 CFU/ml → 4 aliquots | 2.5 CFU/ml → 4 aliquots | 1.25 CFU/ml → 4 aliquots | 0 CFU/ml → 8 aliquots |
| | Extract DNA and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 2x PCR NTC and 2x PCR PC. | | | | | | | |
| 2 | Spike DMEM + 5 % FBS with <i>Clostridium sporogenes</i> | | | | | | | |
| | 99 CFU/ml → 4 aliquots | 50 CFU/ml → 4 aliquots | 25 CFU/ml → 4 aliquots | 10 CFU/ml → 4 aliquots | 5 CFU/ml → 4 aliquots | 2.5 CFU/ml → 4 aliquots | 1.25 CFU/ml → 4 aliquots | 0 CFU/ml → 8 aliquots |
| | Extract DNA and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 2x PCR NTC and 2x PCR PC. | | | | | | | |
| 3 | Spike DMEM + 5 % FBS with <i>Pseudomonas aeruginosa</i> | | | | | | | |
| | 99 CFU/ml → 4 aliquots | 50 CFU/ml → 4 aliquots | 25 CFU/ml → 4 aliquots | 10 CFU/ml → 4 aliquots | 5 CFU/ml → 4 aliquots | 2.5 CFU/ml → 4 aliquots | 1.25 CFU/ml → 4 aliquots | 0 CFU/ml → 8 aliquots |
| | Extract DNA and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 2x PCR NTC and 2x PCR PC. | | | | | | | |
| 4 | Spike DMEM + 5 % FBS with <i>Staphylococcus aureus</i> | | | | | | | |
| | 99 CFU/ml → 4 aliquots | 50 CFU/ml → 4 aliquots | 25 CFU/ml → 4 aliquots | 10 CFU/ml → 4 aliquots | 5 CFU/ml → 4 aliquots | 2.5 CFU/ml → 4 aliquots | 1.25 CFU/ml → 4 aliquots | 0 CFU/ml → 8 aliquots |
| | Extract DNA and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 2x PCR NTC and 2x PCR PC. | | | | | | | |
| 5 | Spike DMEM + 5 % FBS with <i>Streptococcus pyogenes</i> | | | | | | | |
| | 99 CFU/ml → 4 aliquots | 50 CFU/ml → 4 aliquots | 25 CFU/ml → 4 aliquots | 10 CFU/ml → 4 aliquots | 5 CFU/ml → 4 aliquots | 2.5 CFU/ml → 4 aliquots | 1.25 CFU/ml → 4 aliquots | 0 CFU/ml → 8 aliquots |
| | Extract DNA and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 2x PCR NTC and 2x PCR PC. | | | | | | | |

In the event that, after the first assay, two or more samples of a given concentration are negative, the following concentrations of the series were excluded from the study for the next assays.

Tests of Table 13B were performed three times to generate at least six results for each CFU concentration and three NECs.

Table 13B: Test setup for LOD₉₅ determination with Bacteria SR Mix of Microsart® ATMP Sterile Release.

| Detection Limit | | |
|-----------------|---|------------------------------|
| 6 | Spike DMEM + 5 % FBS with <i>Bacillus subtilis</i> | |
| | 2 aliquots 99 CFU/ml + 1 NEC | 2 aliquots 25 CFU/ml + 1 NEC |
| | Extract DNA and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 1x PCR NTC and 1x PCR PC. | |
| 7 | Spike DMEM + 5 % FBS with <i>Clostridium sporogenes</i> | |
| | 2 aliquots 99 CFU/ml + 1 NEC | 2 aliquots 50 CFU/ml + 1 NEC |
| | Extract DNA and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 1x PCR NTC and 1x PCR PC. | |

All tests of Table 14 were performed two times to generate at least eight results for each CFU concentration of each of the bacterial species and 16 results for the NEC.

Table 14. Test setup for LOD₉₅ determination

| Detection Limit | | | | | | |
|-----------------|---|---------------------------|---------------------------|--------------------------|----------------------------|--------------------------|
| 8 | Spike DMEM + 5 % FBS with <i>Bacteroides vulgatus</i> | | | | | |
| | 99 CFU/ml → 4 aliquots | 50 CFU/ml → 4 aliquots | 10 CFU/ml → 4 aliquots | 5 CFU/ml → 4 aliquots | 2.5 CFU/ml → 4 aliquots | 0 CFU/ml → 8 aliquots |
| | Extract DNA and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 2x PCR NTC and 2x PCR PC. | | | | | |
| 9 | Spike DMEM + 5 % FBS with <i>Escherichia coli</i> | | | | | |
| | 99 CFU/ml → 4 aliquots | 50 CFU/ml → 4 aliquots | 10 CFU/ml → 4 aliquots | 5 CFU/ml → 4 aliquots | 2.5 CFU/ml → 4 aliquots | 0 CFU/ml → 8 aliquots |
| | Extract DNA and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 2x PCR NTC and 2x PCR PC. | | | | | |
| 10 | Spike DMEM + 5 % FBS with <i>Pseudomonas protegens</i> | | | | | |
| | 99 CFU/ml → 4 aliquots | 50 CFU/ml → 4 aliquots | 10 CFU/ml → 4 aliquots | 5 CFU/ml → 4 aliquots | 2.5 CFU/ml → 4 aliquots | 0 CFU/ml → 8 aliquots |
| | Extract DNA and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 2x PCR NTC and 2x PCR PC. | | | | | |
| 11 | Spike DMEM + 5 % FBS with <i>Bacillus cereus</i> | | | | | |
| | 99 CFU/ml → 4 aliquots | 50 CFU/ml → 4 aliquots | 10 CFU/ml → 4 aliquots | 5 CFU/ml → 4 aliquots | 2.5 CFU/ml → 4 aliquots | 0 CFU/ml → 8 aliquots |
| | Extract DNA and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 2x PCR NTC and 2x PCR PC. | | | | | |

| | | | | | | |
|----|---|---------------------------|---------------------------|--------------------------|----------------------------|--------------------------|
| | Extract DNA and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 2x PCR NTC and 2x PCR PC. | | | | | |
| | Spike DMEM + 5 % FBS with <i>Enterococcus faecalis</i> | | | | | |
| 12 | 99 CFU/ml → 4 aliquots | 50 CFU/ml → 4 aliquots | 10 CFU/ml → 4 aliquots | 5 CFU/ml → 4 aliquots | 2.5 CFU/ml → 4 aliquots | 0 CFU/ml → 8 aliquots |
| | Extract DNA and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 2x PCR NTC and 2x PCR PC. | | | | | |
| | Spike DMEM + 5 % FBS with <i>Kocuria rhizophila</i> | | | | | |
| 13 | 99 CFU/ml → 4 aliquots | 50 CFU/ml → 4 aliquots | 10 CFU/ml → 4 aliquots | 5 CFU/ml → 4 aliquots | 2.5 CFU/ml → 4 aliquots | 0 CFU/ml → 8 aliquots |
| | Extract DNA and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 2x PCR NTC and 2x PCR PC. | | | | | |
| | Spike DMEM + 5 % FBS with <i>Staphylococcus epidermidis</i> | | | | | |
| 14 | 99 CFU/ml → 4 aliquots | 50 CFU/ml → 4 aliquots | 10 CFU/ml → 4 aliquots | 5 CFU/ml → 4 aliquots | 2.5 CFU/ml → 4 aliquots | 0 CFU/ml → 8 aliquots |
| | Extract DNA and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 2x PCR NTC and 2x PCR PC. | | | | | |

The cut-off is defined as the lowest bacteria concentration [CFU/ml] which leads in 95 % of the tests to a positive result (23/24 and 8/8 samples have to be positive). For LOD₉₅ determination the instrument CFX96 touch were used.

6.7.2 Specificity of PCR and bacteria detection range

In addition to the species tested for the LOD₉₅ determination, the species listed in table 15 were tested using genomic DNA standards.

The specificity of the method was tested by spiking the PCR master mix with bacterial genomic DNA as described in Table 15. This assay was performed twice in order to collect at least 16 results for each species.

Table 15. Test setup for specificity testing with PCR quantification standards

| Specificity | | |
|-------------|---|--------------|
| | Spike PCR master mix with 10 GC/PCR | |
| 1 | <i>Bacteroides fragilis</i> | → 8 aliquots |
| | <i>Enterobacter cloacae</i> | → 8 aliquots |
| | <i>Klebsiella pneumoniae</i> | → 8 aliquots |
| | <i>Serratia marcescens</i> | → 8 aliquots |
| | <i>Clostridium perfringens</i> | → 8 aliquots |
| | <i>Yersinia enterocolitica</i> | → 8 aliquots |
| | 0 GC/PCR → 8 aliquots | |
| | Perform PCR with 10 µl DNA solution in a final volume of 25 µl + IC. Add 2x PCR PC. | |

6.7.3 Comparison of Microsart® ATMP Bacteria with compendial sterility test

The following assays described in Table 16, compare the Microsart® ATMP Bacteria system with the compendial sterility test.

Table 16: Test setup for comparison between Microsart® ATMP Bacteria and compendial sterility test

| Specificity: Comparison with culture method with defined starting material quantity at external contract lab | | |
|--|---|---|
| | Spike DMEM + 5 % FBS with <i>Bacillus subtilis</i> at 2x LOD ₉₅ , LOD ₉₅ and LOD ₉₅ /2. One aliquot without spike is processed as NC. | |
| 1 | 1 ml of each sample is used for the sterility test (direct inoculation) at the external contract labor L+S | Extract DNA from 1ml starting material with Microsart® ATMP Extraction. Perform the qPCR according to Microsart® ATMP Bacteria. |
| | Spike DMEM + 5 % FBS with <i>Clostridium sporogenes</i> at 2x LOD ₉₅ , LOD ₉₅ and LOD ₉₅ /2. One aliquot without spike is processed as NC. | |
| 2 | 1 ml of each sample is used for the sterility test (direct inoculation) at the external contract labor L+S | Extract DNA from 1ml starting material with Microsart® ATMP Extraction. Perform the qPCR according to Microsart® ATMP Bacteria. |
| | Spike DMEM + 5 % FBS with <i>Pseudomonas aeruginosa</i> at 2x LOD ₉₅ , LOD ₉₅ and LOD ₉₅ /2. One aliquot without spike is processed as NC. | |
| 3 | 1 ml of each sample is used for the sterility test (direct inoculation) at the external contract labor L+S | Extract DNA from 1ml starting material with Microsart® ATMP Extraction. Perform the qPCR according to Microsart® ATMP Bacteria. |
| | Spike DMEM + 5 % FBS with <i>Staphylococcus aureus</i> at 2x LOD ₉₅ , LOD ₉₅ and LOD ₉₅ /2. One aliquot without spike is processed as NC. | |
| 5 | 1 ml of each sample is used for the sterility test (direct inoculation) at the external contract labor L+S | Extract DNA from 1ml starting material with Microsart® ATMP Extraction. Perform the qPCR according to Microsart® ATMP Bacteria. |
| 5 | Spike DMEM + 5 % FBS with <i>Streptococcus pyogenes</i> at 2x LOD ₉₅ , LOD ₉₅ and LOD ₉₅ /2. One aliquot without spike is processed as NC. | |

| | | |
|---|--|---|
| | 1 ml of each sample is used for the sterility test (direct inoculation) at the external contract labor L+S | Extract DNA from 1ml starting material with Microsart® ATMP Extraction. Perform the qPCR according to Microsart® ATMP Bacteria. |
| 6 | Spike DMEM + 5 % FBS with <i>Pseudomonas protegens</i> at 2x LOD ₉₅ , LOD ₉₅ and LOD ₉₅ /2. One aliquot without spike is processed as NC. | |
| | 1 ml of each sample is used for the sterility test (direct inoculation) at the external contract labor L+S | Extract DNA from 1ml starting material with Microsart® ATMP Extraction. Perform the qPCR according to Microsart® ATMP Bacteria. |

EZ-CFU of the six species listed in Table 16 were rehydrated in 2 ml of rehydration buffer according to the user manual. The suspensions were diluted to generate the appropriate concentrations and split into aliquots. A sample of each concentration were used for sterility test (direct inoculation) at L+S. In parallel, aliquots were extracted in duplicates and analyzed on a CFX96 cyler.

6.7.4 Robustness

Robustness testing allowed to test the reproducibility of the assay when the conditions of the experiments were slightly modified. Thus, as detailed in Table 17A, we tested the Microsart® ATMP Bacteria system with cell suspension, with free DNA as well as with different PCR cyclers. Assay 1 to 4 were performed twice.

The Bacteria SR Mix of Microsart® ATMP Sterile Release was also, as detailed in Table 17B, tested with different PCR cyclers. The assay was performed three times.

Table 17A. Test setup for robustness testing for Microsart® ATMP Bacteria

| Robustness | | | | | |
|--|---|---------------------------------------|---------------------------------------|--------------------------|-------------------------------------|
| 1 | Dilute cell samples listed in table 4 in DMEM with 5 % FBS to generate a concentration of 10 ⁶ and 10 ⁵ cells/ml. | | | | |
| | Spike with 99 CFU/ml of <i>Bacillus subtilis</i> . → 2 aliquots with 10 ⁶ cells/ml → 2 aliquots with 10 ⁵ cells/ml | no spike (NEC) → 2 aliquots | | | |
| Add 20 µl Internal Control DNA into lysis buffer to monitor the extraction process. Extract DNA. Perform PCR with 10 µl DNA extract in a final volume of 25 µl. Add 2x PCR NTC and 2x PCR PC (add IC to NTC and PC reactions). | | | | | |
| 2 | Spike DMEM + 5 % FBS with 99 CFU/ml of <i>Clostridium sporogenes</i> . → 8 aliquots | | | | |
| | Extract DNA and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 2x PCR NTC and 2x PCR PC. | | | | NEC (DMEM + 5% FBS) → 2 aliquots |
| Rotor Gene 6000 | | ABI 7500 | Mx3005P | CFX96 | |
| 3 | Spike water with <i>Escherichia coli</i> gDNA. | | | | |
| | 10 ⁴ GC/ml → 8 aliquots | 10 ³ GC/ml → 8 aliquots | 10 ² GC/ml → 8 aliquots | 10 GC/ml → 8 aliquots | 0 GC/ml (NEC) → 8 aliquots |
| Extract DNA Perform PCR with 10 µl of extract in a final volume of 25 µl + IC. In parallel, perform a standard PCR serie with 2x10 µl of each of the spiked water (not extracted). Add 2x PCR NTC and 2x PCR PC. | | | | | |
| 4 | Spike water with cell culture suspension (Vero cells; 10 ⁴ cells/ml) and <i>Escherichia coli</i> gDNA. | | | | |
| | 10 ⁴ GC/ml → 8 aliquots | 10 ³ GC/ml → 8 aliquots | 10 ² GC/ml → 8 aliquots | 10 GC/ml → 8 aliquots | 0 GC/ml (NEC) → 8 aliquots |
| Extract DNA Perform PCR with 10 µl of extract in a final volume of 25 µl + IC. In parallel, perform a standard PCR serie with 2x10 µl of each of the spiked water (not extracted). Add 2x PCR PC. | | | | | |
| 5 | Extract DNA from culture media listed in Table 2 and from DMEM + 5 % FCS and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 2x PCR PC. | | | | |
| | 12 x 8 for DMEM; 1 x 8 for other culture media | | | | |

7 Study Results

The study conditions had to provide information on all relevant validation parameters requested by European Pharmacopoeia (Ph. Eur.) chapter 5.1.6 part 4-1-1, Primary validation to be performed by the supplier.

7.1 LOD₉₅ Detection Limit

As the method employed is used only to obtain a qualitative result, proof of linearity is not required. If however the concept of linearity is extended to cover the working range, the detection limit becomes extremely important. In practice, the detection limit is determined in the form of the positive threshold (i.e. the cut-off point in the form of the minimum number of amplified target sequences by volume positively detected in 95 % of the sample series).

| Link | Procedure | Acceptance Criterion | Results / LOD ₉₅ |
|---|--|--|---|
| See Table 13A; 1 to 5 See Table 13B: 6 to 7 See Table 14; 8 to 14 | The EZ-CFU of each bacterial species (Table 13, 14 and 15) will be diluted, according to their individual cell count, in DMEM + 5 % FBS to prepare suspensions with concentrations from 99 to 0 CFU/ml. Individual dilution series will be prepared for the five bacterial species listed in EP 2.6.1 and EP 2.6.27, available as EZ-CFU, and for another seven bacterial species. Dilutions from 99 to 0 CFU/ml will be tested according to test procedure described chapter 6. | The cut-off is defined as the lowest bacteria concentration [CFU/ml] which leads in 95 % of the tests to a positive result (23/24 and 8/8 samples have to be positive). LOD ₉₅ must be ≤ 99CFU | Passed (LOD ₉₅ comprised between 2.5 CFU and 99 CFU) |

Bacillus subtilis (Microsart® ATMP Bacteria)

| CFU/ml | | | | | | Mean | |
|--------|-------|-------------------|-------------------|-------------------|-------------------|-------|-------|
| 99 | Run 1 | 31.04 | 31.31 | 31.17 | 31.35 | 31.22 | 24/24 |
| | Run 2 | 31.79 | 31.52 | 31.11 | 30.89 | 31.33 | |
| | Run 3 | 31.10 | 31.43 | 31.16 | 30.51 | 31.05 | |
| | Run 4 | 31.40 | 30.96 | 31.15 | 31.07 | 31.14 | |
| | Run 5 | 31.39 | 31.29 | 32.01 | 31.40 | 31.52 | |
| | Run 6 | 31.46 | 30.76 | 31.31 | 32.99 | 31.63 | |
| 50 | Run 1 | 33.05 | 32.15 | 32.93 | 32.96 | 32.77 | 24/24 |
| | Run 2 | 33.25 | 32.65 | 39.39 | 32.21 | 34.37 | |
| | Run 3 | 32.13 | 32.29 | 32.37 | 32.79 | 32.39 | |
| | Run 4 | 33.31 | 30.65 | 32.15 | 33.21 | 32.33 | |
| | Run 5 | 31.50 | 32.35 | 32.37 | 34.01 | 32.56 | |
| | Run 6 | 31.78 | 32.16 | 32.19 | 32.17 | 32.07 | |
| 25 | Run 1 | 34.36 | 34.10 | 34.45 | 33.46 | 34.09 | 23/24 |
| | Run 2 | 33.33 | 33.65 | 31.31 | 33.34 | 32.91 | |
| | Run 3 | 33.17 | 32.18 | 31.10 | 32.74 | 32.29 | |
| | Run 4 | 32.54 | 35.36 | 34.07 | 33.91 | 33.97 | |
| | Run 5 | 35.07 | 33.26 | 35.06 | 34.11 | 34.37 | |
| | Run 6 | No C _q | 32.90 | 34.97 | 34.16 | 34.01 | |
| 10 | Run 1 | 37.09 | 36.67 | 35.57 | No C _q | 36.44 | 22/24 |
| | Run 2 | 34.38 | 34.86 | 34.59 | 34.70 | 34.63 | |
| | Run 3 | 33.91 | 34.25 | 33.67 | 34.05 | 33.97 | |
| | Run 4 | 34.02 | 34.66 | 35.70 | 34.34 | 34.68 | |
| | Run 5 | 35.59 | 33.79 | 35.12 | No C _q | 34.83 | |
| | Run 6 | 34.42 | 33.41 | 34.99 | 34.65 | 34.37 | |
| 5 | Run 1 | 38.55 | 36.84 | 39.42 | 34.99 | 37.45 | 18/24 |
| | Run 2 | 38.63 | No C _q | No C _q | No C _q | 38.63 | |
| | Run 3 | No C _q | No C _q | No C _q | 36.89 | 36.89 | |
| | Run 4 | 35.33 | 39.67 | 37.04 | 33.20 | 36.31 | |
| | Run 5 | 35.64 | 37.28 | 36.25 | 35.36 | 36.13 | |
| | Run 6 | 36.28 | 36.84 | 37.76 | 37.00 | 36.97 | |

Bacillus subtilis (Microsart® ATMP Sterile Release)

| CFU/ml | | | | Mean | |
|--------|-------|-------|-------|-------|-----|
| 99 | Run 1 | 32.41 | 31.07 | 31.74 | 6/6 |
| | Run 2 | 32.35 | 34.42 | 33.38 | |
| | Run 3 | 33.05 | 31.53 | 32.29 | |
| 25 | Run 1 | 35.38 | 33.39 | 34.38 | 6/6 |
| | Run 2 | 35.42 | 35.23 | 35.32 | |
| | Run 3 | 34.34 | 33.53 | 33.93 | |

Clostridium sporogenes (Microsart® ATMP Bacteria)

| CFU/ml | | | | | Mean | | |
|--------|-------|-------------------|-------------------|-------------------|-------------------|-------|-------|
| 99 | Run 1 | 33.04 | 33.42 | 33.13 | 34.74 | 33.58 | 24/24 |
| | Run 2 | 33.48 | 33.33 | 33.97 | 34.05 | 33.70 | |
| | Run 3 | 34.01 | 33.53 | 34.03 | 33.90 | 33.87 | |
| | Run 4 | 32.85 | 32.30 | 33.24 | 33.69 | 33.02 | |
| | Run 5 | 33.31 | 33.88 | 34.00 | 33.29 | 33.62 | |
| | Run 6 | 33.72 | 33.79 | 34.44 | 33.94 | 33.98 | |
| 50 | Run 1 | 34.07 | 35.01 | 34.21 | 35.42 | 34.68 | 23/24 |
| | Run 2 | 35.60 | 36.56 | 35.40 | 35.50 | 35.76 | |
| | Run 3 | 34.57 | 34.34 | 34.50 | 35.02 | 34.61 | |
| | Run 4 | 34.50 | 34.89 | 34.76 | No C _q | 34.72 | |
| | Run 5 | 35.39 | 35.95 | 38.41 | 35.53 | 36.32 | |
| | Run 6 | 35.85 | 35.97 | 35.81 | 37.24 | 36.22 | |
| 25 | Run 1 | 39.12 | 36.14 | 35.71 | 36.83 | 36.95 | 19/24 |
| | Run 2 | No C _q | 37.22 | 37.12 | 38.07 | 37.47 | |
| | Run 3 | 39.24 | 36.85 | No C _q | 36.52 | 37.54 | |
| | Run 4 | 37.04 | 36.76 | 35.77 | 38.09 | 36.91 | |
| | Run 5 | No C _q | No C _q | No C _q | 38.38 | 38.38 | |
| | Run 6 | 38.54 | 36.47 | 38.87 | 39.27 | 38.29 | |

Clostridium sporogenes (Microsart® ATMP Sterile Release)

| CFU/ml | | | | Mean | |
|--------|-------|-------|-------|-------|-----|
| 99 | Run 1 | 35.41 | 33.40 | 34.40 | 6/6 |
| | Run 2 | 35.14 | 34.30 | 34.72 | |
| | Run 3 | 34.57 | 34.71 | 34.64 | |
| 50 | Run 1 | 35.46 | 34.46 | 34.96 | 6/6 |
| | Run 2 | 34.86 | 34.42 | 34.64 | |
| | Run 3 | 35.39 | 34.70 | 35.04 | |

Pseudomonas aeruginosa

| CFU/ml | | | | | Mean | | |
|--------|-------|-------|-------|-------|-------|-------|-------|
| 99 | Run 1 | 29.02 | 29.07 | 29.21 | 29.16 | 29.11 | 24/24 |
| | Run 2 | 30.67 | 31.01 | 31.35 | 31.35 | 31.09 | |
| | Run 3 | 30.07 | 30.53 | 30.22 | 39.94 | 32.69 | |
| | Run 4 | 30.50 | 31.14 | 31.23 | 30.53 | 30.85 | |
| | Run 5 | 31.52 | 30.74 | 30.76 | 31.76 | 31.19 | |
| | Run 6 | 30.36 | 30.92 | 31.35 | 30.75 | 30.84 | |
| 50 | Run 1 | 31.27 | 31.42 | 31.13 | 31.10 | 31.23 | 24/24 |
| | Run 2 | 32.17 | 31.98 | 31.85 | 31.45 | 31.86 | |
| | Run 3 | 31.82 | 31.58 | 31.61 | 32.12 | 31.78 | |
| | Run 4 | 32.31 | 32.14 | 33.08 | 32.01 | 32.38 | |
| | Run 5 | 33.13 | 32.24 | 32.30 | 32.37 | 32.51 | |
| | Run 6 | 32.05 | 32.43 | 32.65 | 32.14 | 32.32 | |
| 25 | Run 1 | 32.93 | 31.48 | 31.92 | 32.13 | 32.11 | 24/24 |
| | Run 2 | 32.65 | 32.28 | 32.51 | 33.27 | 32.68 | |
| | Run 3 | 32.24 | 32.10 | 31.92 | 32.00 | 32.06 | |
| | Run 4 | 33.06 | 33.72 | 33.07 | 33.42 | 33.32 | |
| | Run 5 | 33.50 | 33.46 | 33.33 | 33.50 | 33.45 | |

| CFU/ml | | | | | | Mean | |
|--------|-------|-------|-------|-------------------|-------------------|-------|-------|
| 10 | Run 6 | 33.44 | 33.52 | 33.21 | 32.63 | 33.20 | 24/24 |
| | Run 1 | 32.88 | 32.87 | 32.63 | 33.29 | 32.92 | |
| | Run 2 | 33.70 | 33.26 | 33.46 | 33.66 | 33.52 | |
| | Run 3 | 32.38 | 33.18 | 32.91 | 33.34 | 32.95 | |
| | Run 4 | 34.34 | 34.22 | 34.60 | 34.87 | 34.51 | |
| | Run 5 | 34.39 | 33.93 | 36.64 | 34.19 | 34.79 | |
| 5 | Run 6 | 34.02 | 33.95 | 34.47 | 34.94 | 34.34 | 24/24 |
| | Run 1 | 34.23 | 35.43 | 34.45 | 34.48 | 34.65 | |
| | Run 2 | 36.10 | 36.52 | 37.06 | 35.92 | 36.40 | |
| | Run 3 | 34.05 | 34.43 | 34.07 | 34.65 | 34.30 | |
| | Run 4 | 35.44 | 34.66 | 34.98 | 35.59 | 35.17 | |
| | Run 5 | 35.21 | 35.51 | 34.41 | 35.14 | 35.07 | |
| 2.5 | Run 6 | 34.66 | 35.48 | 36.33 | 35.05 | 35.38 | 20/24 |
| | Run 1 | 36.16 | 37.32 | No C _q | 36.21 | 36.56 | |
| | Run 2 | 37.16 | 38.46 | 37.37 | No C _q | 37.66 | |
| | Run 3 | 36.19 | 36.62 | 37.25 | 39.12 | 37.29 | |
| | Run 4 | 34.22 | 37.10 | No C _q | 36.64 | 35.99 | |
| | Run 5 | 36.22 | 35.96 | 35.14 | 36.58 | 35.97 | |
| | Run 6 | 35.22 | 38.45 | 35.31 | No C _q | 36.33 | |

Staphylococcus aureus

| CFU/ml | | | | | | Mean | |
|--------|-------|-------------------|-------------------|-------|-------------------|-------|-------|
| 99 | Run 1 | 33.24 | 33.28 | 33.11 | 32.29 | 32.98 | 24/24 |
| | Run 2 | 33.43 | 32.51 | 32.11 | 32.79 | 32.71 | |
| | Run 3 | 31.17 | 31.27 | 31.41 | 31.43 | 31.32 | |
| | Run 4 | 33.15 | 33.16 | 33.35 | 32.44 | 33.02 | |
| | Run 5 | 32.56 | 33.05 | 32.15 | 33.45 | 32.80 | |
| | Run 6 | 32.00 | 33.12 | 32.06 | 32.55 | 32.43 | |
| 50 | Run 1 | 35.51 | 34.84 | 33.53 | 34.07 | 34.49 | 24/24 |
| | Run 2 | 33.65 | 34.48 | 34.33 | 33.89 | 34.09 | |
| | Run 3 | 32.62 | 32.39 | 32.09 | 32.13 | 32.31 | |
| | Run 4 | 34.42 | 34.90 | 34.00 | 34.25 | 34.39 | |
| | Run 5 | 33.82 | 34.51 | 34.93 | 33.70 | 34.24 | |
| | Run 6 | 33.82 | 33.48 | 34.29 | 33.10 | 33.67 | |
| 25 | Run 1 | 36.04 | 36.94 | 36.14 | 37.80 | 36.73 | 23/24 |
| | Run 2 | 35.02 | 35.72 | 34.98 | 34.53 | 35.06 | |
| | Run 3 | 32.94 | 34.12 | 32.95 | 32.09 | 33.02 | |
| | Run 4 | 35.46 | No C _q | 37.08 | 35.02 | 35.85 | |
| | Run 5 | 35.31 | 34.17 | 34.70 | 35.48 | 34.91 | |
| | Run 6 | 34.32 | 34.18 | 35.47 | 36.96 | 35.23 | |
| 10 | Run 1 | No C _q | 38.02 | 37.05 | No C _q | 37.54 | 22/24 |
| | Run 2 | 36.11 | 39.54 | 35.62 | 31.45 | 35.68 | |
| | Run 3 | 34.36 | 34.50 | 34.59 | 34.22 | 34.42 | |
| | Run 4 | 38.68 | 37.72 | 36.77 | 37.17 | 37.58 | |
| | Run 5 | 37.26 | 35.73 | 37.02 | 38.83 | 37.21 | |
| | Run 6 | 38.00 | 35.76 | 37.01 | 35.38 | 36.54 | |

Streptococcus pyogenes

| CFU/ml | | | | | | Mean | |
|--------|-------|-------------------|-------|-------------------|-------------------|-------|-------|
| 99 | Run 1 | 34.42 | 34.06 | 34.44 | 34.75 | 34.42 | 24/24 |
| | Run 2 | 33.61 | 35.89 | 36.89 | 33.98 | 35.09 | |
| | Run 3 | 35.41 | 34.92 | 36.88 | 35.01 | 35.55 | |
| | Run 4 | 34.87 | 37.03 | 35.58 | 35.95 | 35.86 | |
| | Run 5 | 34.22 | 34.48 | 34.25 | 34.11 | 34.26 | |
| | Run 6 | 34.44 | 34.87 | 34.81 | 34.69 | 34.70 | |
| 50 | Run 1 | 37.01 | 37.52 | No C _q | 36.76 | 37.10 | 18/24 |
| | Run 2 | 35.61 | 35.37 | 35.17 | 35.29 | 35.36 | |
| | Run 3 | No C _q | 37.70 | No C _q | No C _q | 37.70 | |
| | Run 4 | 37.83 | 38.31 | No C _q | No C _q | 38.07 | |

| CFU/ml | | | | | | Mean | |
|--------|-------|-------------------|-------------------|-------------------|-------------------|-------------------|-------|
| | Run 5 | 34.50 | 35.25 | 35.29 | 35.34 | 35.10 | |
| | Run 6 | 35.84 | 35.95 | 35.03 | 35.25 | 35.52 | |
| 25 | Run 1 | 38.28 | No C _q | 36.47 | No C _q | 37.37 | 13/24 |
| | Run 2 | 38.09 | 38.78 | No C _q | No C _q | 38.43 | |
| | Run 3 | No C _q | No C _q | 39.17 | No C _q | 39.17 | |
| | Run 4 | No C _q | No C _q | No C _q | No C _q | No C _q | |
| | Run 5 | 37.56 | 36.29 | 36.86 | 37.41 | 37.03 | |
| | Run 6 | 36.69 | 37.52 | 37.15 | 36.69 | 37.01 | |

Bacteroides vulgatus

| CFU/ml | | | | | | Mean | |
|--------|-------|-------|-------|-------|-------|-------|-----|
| 99 | Run 1 | 19.71 | 19.92 | 19.95 | 20.74 | 20.08 | 8/8 |
| | Run 2 | 20.09 | 19.90 | 20.06 | 19.86 | 19.98 | |
| 50 | Run 1 | 20.66 | 20.74 | 20.59 | 21.26 | 20.81 | 8/8 |
| | Run 2 | 20.45 | 21.03 | 20.21 | 21.47 | 20.79 | |
| 10 | Run 1 | 23.33 | 22.88 | 22.77 | 23.35 | 23.08 | 8/8 |
| | Run 2 | 22.99 | 22.97 | 23.18 | 22.96 | 23.02 | |
| 5 | Run 1 | 23.66 | 24.21 | 23.73 | 24.06 | 23.91 | 8/8 |
| | Run 2 | 23.97 | 24.57 | 25.02 | 25.15 | 24.68 | |
| 2.5 | Run 1 | 26.25 | 25.73 | 24.85 | 24.65 | 25.37 | 8/8 |
| | Run 2 | 25.38 | 25.72 | 25.09 | 25.10 | 25.32 | |

Escherichia coli

| CFU/ml | | | | | | Mean | |
|--------|-------|-------|-------|-------|-------------------|-------|-----|
| 99 | Run 1 | 32.44 | 33.17 | 32.79 | 32.18 | 32.64 | 8/8 |
| | Run 2 | 31.40 | 31.56 | 31.16 | 31.63 | 31.44 | |
| 50 | Run 1 | 33.70 | 33.45 | 35.40 | 33.06 | 33.90 | 8/8 |
| | Run 2 | 32.07 | 33.17 | 33.07 | 32.63 | 32.73 | |
| 10 | Run 1 | 35.96 | 34.53 | 34.48 | 35.04 | 35.00 | 8/8 |
| | Run 2 | 34.49 | 33.97 | 34.46 | 34.32 | 34.31 | |
| 5 | Run 1 | 35.25 | 34.71 | 35.11 | No C _q | 35.02 | 6/8 |
| | Run 2 | 35.41 | 36.09 | 36.03 | No C _q | 35.84 | |
| 2.5 | Run 1 | 35.59 | 34.68 | 37.94 | 35.62 | 35.96 | 8/8 |
| | Run 2 | 36.66 | 34.76 | 36.57 | 36.70 | 36.17 | |

Pseudomonas protegens

| CFU/ml | | | | | | Mean | |
|--------|-------|-------|-------------------|-------------------|-------|-------|-----|
| 99 | Run 1 | 32.17 | 31.88 | 32.02 | 33.56 | 32.40 | 8/8 |
| | Run 2 | 32.79 | 33.14 | 32.42 | 33.01 | 32.84 | |
| 50 | Run 1 | 32.97 | 32.98 | 33.73 | 33.22 | 33.22 | 8/8 |
| | Run 2 | 33.77 | 34.15 | 34.06 | 34.01 | 34.00 | |
| 10 | Run 1 | 37.16 | 37.32 | 36.00 | 35.63 | 36.53 | 8/8 |
| | Run 2 | 37.74 | 36.28 | 36.67 | 36.72 | 36.85 | |
| 5 | Run 1 | 37.05 | 36.63 | No C _q | 37.27 | 36.98 | 7/8 |
| | Run 2 | 37.35 | 36.48 | 38.05 | 37.94 | 37.45 | |
| 2.5 | Run 1 | 36.47 | 36.71 | 37.81 | 35.86 | 36.71 | 7/8 |
| | Run 2 | 37.90 | No C _q | 38.05 | 37.37 | 37.77 | |

Bacillus cereus

| CFU/ml | | | | | | Mean | |
|--------|-------|-------|-------|-------|-------|-------|-----|
| 99 | Run 1 | 32.51 | 32.11 | 31.73 | 32.27 | 32.15 | 8/8 |
| | Run 2 | 32.16 | 32.40 | 32.17 | 32.03 | 32.19 | |
| 50 | Run 1 | 32.93 | 34.20 | 33.76 | 34.00 | 33.72 | 8/8 |

| | | | | | | | |
|-----|-------|-------|-------------------|-------|-------------------|-------|-----|
| 10 | Run 2 | 34.62 | 33.36 | 33.36 | 33.44 | 33.69 | 8/8 |
| | Run 1 | 36.11 | 35.97 | 36.00 | 35.62 | 35.92 | |
| 5 | Run 2 | 35.02 | 36.28 | 34.64 | 34.47 | 35.10 | 8/8 |
| | Run 1 | 35.03 | 37.25 | 36.62 | 37.05 | 36.49 | |
| 2.5 | Run 2 | 36.17 | 37.39 | 36.30 | 36.27 | 36.53 | 6/8 |
| | Run 1 | 36.78 | No C _q | 37.05 | No C _q | 36.91 | |
| | Run 2 | 39.73 | 36.88 | 35.54 | 36.85 | 37.25 | |

Enterococcus faecalis

| CFU/ml | | | | | | Mean | |
|--------|-------|-------------------|-------------------|-------------------|-------|-------|-----|
| 99 | Run 1 | 34.52 | 34.72 | 34.19 | 34.84 | 34.57 | 8/8 |
| | Run 2 | 33.15 | 35.66 | 36.48 | 36.03 | 35.33 | |
| 50 | Run 1 | No C _q | 36.12 | 36.78 | 35.63 | 36.18 | 7/8 |
| | Run 2 | 36.54 | 36.80 | 37.03 | 36.73 | 36.77 | |
| 10 | Run 1 | 36.44 | 36.33 | 38.51 | 37.95 | 37.31 | 8/8 |
| | Run 2 | 36.25 | 37.25 | 37.51 | 38.62 | 37.41 | |
| 5 | Run 1 | No C _q | 37.75 | 36.48 | 36.84 | 37.02 | 6/8 |
| | Run 2 | 35.64 | No C _q | 37.61 | 38.44 | 37.23 | |
| 2.5 | Run 1 | 38.24 | 37.37 | No C _q | 39.58 | 38.40 | 6/8 |
| | Run 2 | 36.86 | 38.11 | No C _q | 39.03 | 38.00 | |

Kocuria rhizophila

| CFU/ml | | | | | | Mean | |
|--------|-------|-------------------|-------|-------|-------|-------|-----|
| 99 | Run 1 | 31.79 | 32.29 | 32.04 | 32.12 | 32.06 | 8/8 |
| | Run 2 | 35.34 | 32.62 | 33.35 | 32.54 | 33.46 | |
| 50 | Run 1 | 33.07 | 33.08 | 33.04 | 33.08 | 33.07 | 8/8 |
| | Run 2 | 33.51 | 34.76 | 33.86 | 33.40 | 33.88 | |
| 10 | Run 1 | 35.48 | 35.12 | 35.07 | 35.32 | 35.25 | 8/8 |
| | Run 2 | 37.51 | 39.23 | 36.33 | 37.59 | 37.66 | |
| 5 | Run 1 | 35.76 | 35.76 | 37.58 | 35.64 | 36.18 | 7/8 |
| | Run 2 | No C _q | 36.65 | 35.52 | 36.20 | 36.12 | |
| 2.5 | Run 1 | 37.89 | 35.83 | 38.31 | 37.91 | 37.48 | 8/8 |
| | Run 2 | 38.06 | 37.52 | 37.39 | 37.87 | 37.71 | |

Staphylococcus epidermis

| CFU/ml | | | | | | Mean | |
|--------|-------|-------------------|-------------------|-------------------|-------------------|-------------------|-----|
| 99 | Run 1 | 35.84 | 38.19 | 34.63 | 35.09 | 35.94 | 8/8 |
| | Run 2 | 37.95 | 38.65 | 37.14 | 35.88 | 37.40 | |
| 50 | Run 1 | 36.10 | No C _q | 36.66 | 39.99 | 37.58 | 5/8 |
| | Run 2 | 32.66 | No C _q | No C _q | 37.62 | 35.14 | |
| 10 | Run 1 | 35.87 | No C _q | 39.77 | 38.41 | 38.02 | 3/8 |
| | Run 2 | No C _q | No C _q | No C _q | No C _q | No C _q | |
| 5 | Run 1 | No C _q | No C _q | No C _q | No C _q | No C _q | 0/8 |
| | Run 2 | No C _q | No C _q | No C _q | No C _q | No C _q | |
| 2.5 | Run 1 | No C _q | No C _q | No C _q | No C _q | No C _q | 0/8 |
| | Run 2 | No C _q | No C _q | No C _q | No C _q | No C _q | |

LOD₉₅ summary

| Species | LOD ₉₅ |
|--------------------------|-------------------|
| Table 13 | |
| <i>Bacillus subtilis</i> | 25 CFU/ml |

| | |
|---------------------------------|------------|
| <i>Clostridium sporogenes</i> | 50 CFU/ml |
| <i>Pseudomonas aeruginosa</i> | 5 CFU/ml |
| <i>Staphylococcus aureus</i> | 25 CFU/ml |
| <i>Streptococcus pyogenes</i> | 99 CFU/ml |
| Table 14 | |
| <i>Bacteroides vulgatus</i> | 2.5 CFU/ml |
| <i>Escherichia coli</i> | 10 CFU/ml |
| <i>Pseudomonas protegens</i> | 10 CFU/ml |
| <i>Bacillus cereus</i> | 5 CFU/ml |
| <i>Enterococcus faecalis</i> | 99 CFU/ml |
| <i>Kocuria rhizophila</i> | 10 CFU/ml |
| <i>Staphylococcus epidermis</i> | 99 CFU/ml |

7.2 Specificity

Specificity testing was comprehensively covered during sensitivity and robustness testing. During sensitivity, 12 different bacterial species were tested in order to determine the limit of detection when spiked into a complex sample matrix (DMEM + 5 % FBS). Another six species were tested as PCR quantification standards by spiking directly into PCR master mix and an *in silico* study was performed in order to predict the specificity of the primers. In terms of robustness testing, four samples containing different cell lines in a relevant cell density and in typical cell culture media and buffer were spiked with 99 CFU of one of the bacterial species detected with the highest LOD₉₅ value during LOD determination (selected from the five bacterial species listed in EP 2.6.1 and EP 2.6.27, available as EZ-CFU). Additionally, six species were tested at three concentrations around their LOD₉₅ in comparison with the culture method described in EP 2.6.1.

7.2.1 Sequence Alignment

| Procedure | Acceptance Criterion | Results |
|--|---|--|
| Comparison of all primer sequences with the genomic database of relevant bacterial species. This provides additional information as only a limited number of bacteria can be part of this study. | Bacterial species showing ≤ 3 nucleotides mismatch in the alignment of the primer and probe sequence with the 16S rRNA genome are considered specifically detectable. | 94.7 % of bacteria sequences are putatively detectable based on sequence alignments. |

| Strains of all bacterial species which were part of this study | Primer Mismatches | | |
|--|-------------------|-------|----------------|
| | Forward Primer | Probe | Reverse Primer |
| <i>Bacteroides fragilis</i> ATCC® 25285 | 0 | 0 | 1 |
| <i>Bacteroides vulgatus</i> ATCC® 8482 | 0 | 0 | 1 |
| <i>Enterobacter cloacae</i> subsp. <i>cloacae</i> ATCC® 13047 | 0 | 0 | 0 |
| <i>Escherichia coli</i> ATCC® 8739 | 0 | 0 | 0 |
| <i>Klebsiella pneumoniae</i> ATCC® 13883 | 0 | 0 | 0 |
| <i>Pseudomonas aeruginosa</i> ATCC® 9027 | 0 | 0 | 0 |
| <i>Pseudomonas protegens</i> ATCC® 17386 | 0 | 0 | 0 |
| <i>Serratia marcescens</i> ATCC® 13880 | 0 | 0 | 0 |
| <i>Streptococcus pyogenes</i> ATCC® 19615 | 0 | 0 | 0 |
| <i>Bacillus cereus</i> ATCC® 10876 | 0 | 0 | 0 |
| <i>Bacillus subtilis</i> ATCC® 6633 | 0 | 0 | 0 |
| <i>Clostridium perfringens</i> ATCC® 13124 | 0 | 0 | 0 |
| <i>Clostridium sporogenes</i> ATCC® 3584 | 0 | 0 | 0 |
| <i>Enterococcus faecalis</i> ATCC® 29212 | 0 | 0 | 0 |
| <i>Kocuria rhizophila</i> ATCC® 9341 | 0 | 0 | 2 |
| <i>Propionibacterium acnes</i> ATCC® 6919 | 1 | 0 | 2 |
| <i>Staphylococcus aureus</i> ATCC® 6538 | 0 | 0 | 0 |

| Strains of all bacterial species which were part of this study | Primer Mismatches | | |
|--|-------------------|-------|----------------|
| | Forward Primer | Probe | Reverse Primer |
| <i>Staphylococcus epidermidis</i> ATCC® 12228 | 0 | 0 | 0 |

| | Primer/Probe Mismatches | | | |
|-------------------|-------------------------|-------|-------|-------|
| | 0 | 1 | 2 | 3 |
| Bacteria | 48.8% | 69.4% | 85.7% | 94.7% |
| Archea | n.a | n.a | 0.1% | 40.4% |
| Eukaryotes | 0% | 0% | 0.1% | 0.3% |

7.2.2 Bacteria Detection Range

| Link | Procedure | Acceptance Criterion | Results |
|---|---|--|---------|
| See Table 13A; 1 to 5 See Table 13B; 6 to 7 See Table 14; 8 to 14 | All bacteria listed in Table 13 and 14 were tested at concentrations between 0-99 CFU/ml (spiked into DMEM + 5 % FBS) in 3; 4 or 8 replicates | 99 CFU/ml must be tested positive for all species. | Passed |

| | Average C _q value at 99 CFU/ml | % detected at 99 CFU/ml |
|---|---|-------------------------|
| <i>Bacillus subtilis</i> (Microsart® ATMP Bacteria) | 31.31 | 100 |
| <i>Bacillus subtilis</i> (Microsart® ATMP Sterile Release) | 32.47 | 100 |
| <i>Clostridium sporogenes</i> (Microsart® ATMP Bacteria) | 33.63 | 100 |
| <i>Clostridium sporogenes</i> (Microsart® ATMP Sterile Release) | 34.59 | 100 |
| <i>Pseudomonas aeruginosa</i> | 30.97 | 100 |
| <i>Staphylococcus aureus</i> | 32.55 | 100 |
| <i>Streptococcus pyogenes</i> | 34.98 | 100 |
| <i>Bacteroides vulgatus</i> | 20.05 | 100 |
| <i>Escherichia coli</i> | 32.04 | 100 |
| <i>Pseudomonas protegens</i> | 32.62 | 100 |
| <i>Bacillus cereus</i> | 32.17 | 100 |
| <i>Enterococcus faecalis</i> | 34.95 | 100 |
| <i>Kocuria rhizophila</i> | 32.76 | 100 |
| <i>Staphylococcus epidermidis</i> | 36.67 | 100 |

7.2.3 Sample Matrix effects / Cross reactivity

| Link | Procedure | Acceptance Criterion | Results |
|--------------------------------------|--|---|---------|
| See Table 4 See Table 17, 1 (NEC) | All cell samples listed in Table 4 were tested in duplicates without bacterial spike (NEC during robustness testing) | All samples shall show a negative result. | Passed |

| | | Results |
|---------------|-------------------|---------|
| Hela | No C _q | 0/2 |
| | No C _q | |
| Vero | No C _q | 0/2 |
| | No C _q | |
| CHO-K1 | No C _q | 0/2 |
| | No C _q | |
| RK13 | No C _q | 0/2 |
| | No C _q | |

7.2.4 Specificity of PCR



| Link | Procedure | Acceptance Criterion | Results |
|------|-----------|----------------------|---------|
|------|-----------|----------------------|---------|

| | | | |
|-----------------|--|--|--------|
| See Table 15; 1 | All bacteria listed in Table 16 were tested with 10 and 0 GC (spiked directly into PCR). | All species must be detected at 10 GC/PCR. | Passed |
|-----------------|--|--|--------|

| | | | |
|-----------------------|-------------------|-------------------|------|
| 0 GC/PCR (NTC) | Run 1 | Run 2 | 0/16 |
| | No C _q | No C _q | |
| | No C _q | No C _q | |
| | No C _q | No C _q | |
| | No C _q | No C _q | |
| | No C _q | No C _q | |
| | No C _q | No C _q | |
| | No C _q | No C _q | |

| | Run 1 | Run 2 | |
|--|-------|-------|-------|
| 10GC/PCR <i>Bacteroides fragilis</i> | 33.60 | 34.13 | 16/16 |
| | 33.55 | 33.44 | |
| | 33.78 | 33.61 | |
| | 34.21 | 33.76 | |
| | 33.47 | 33.70 | |
| | 33.79 | 33.95 | |
| | 33.72 | 34.03 | |
| | 34.32 | 34.24 | |
| 10GC/PCR <i>Enterobacter cloacae</i> | 32.07 | 31.93 | 16/16 |
| | 32.02 | 32.26 | |
| | 32.55 | 32.08 | |
| | 32.23 | 32.13 | |
| | 32.89 | 32.03 | |
| | 32.25 | 32.13 | |
| | 32.20 | 32.18 | |
| | 32.46 | 32.11 | |
| 10GC/PCR <i>Klebsiella pneumoniae</i> | 33.43 | 32.76 | 16/16 |
| | 33.55 | 33.32 | |
| | 33.26 | 32.83 | |
| | 33.51 | 33.22 | |
| | 33.22 | 33.41 | |
| | 33.65 | 32.86 | |
| | 33.42 | 33.00 | |
| | 33.66 | 32.96 | |

| | Run 1 | Run 2 | |
|--|-------|-------|-------|
| 10GC/PCR <i>Serratia marcescens</i> | 32.74 | 32.70 | 16/16 |
| | 32.60 | 33.22 | |
| | 32.97 | 32.70 | |
| | 33.39 | 32.90 | |
| | 33.31 | 32.72 | |
| | 33.04 | 32.95 | |
| | 32.85 | 32.95 | |
| | 33.67 | 33.04 | |
| 10GC/PCR <i>Clostridium perfringens</i> | 31.04 | 31.46 | 16/16 |
| | 31.50 | 31.33 | |
| | 31.38 | 31.51 | |
| | 31.81 | 31.34 | |
| | 31.52 | 31.52 | |
| | 31.55 | 31.26 | |
| | 31.57 | 31.23 | |
| | 31.81 | 31.37 | |
| 10GC/PCR <i>Yersinia enterocolitica</i> | 32.91 | 32.76 | 16/16 |
| | 33.01 | 33.05 | |
| | 33.04 | 33.22 | |
| | 33.12 | 33.18 | |
| | 32.99 | 33.40 | |
| | 32.57 | 32.75 | |
| | 33.06 | 32.84 | |
| | 33.51 | 33.45 | |



7.2.5 Comparison of Microsart® ATMP Bacteria with the compendial culture method

| Link | Procedure | Acceptance Criterion | Results |
|--------------|--|---|---------------------------------------|
| See Table 16 | For each species listed in Table 16, a dilution series was performed. 1 ml was extracted with Microsart® ATMP Extraction and analyzed with | Microsart® ATMP Bacteria shall show equal or higher | Passed (100% similarity with culture) |

| | | | |
|--|---|---|-----------------------|
| | Microsart® ATMP Bacteria. In parallel, 1 ml of the species listed in Table 16 were tested with the compendial culture method (direct inoculation) by an external lab. | sensitivity than the culture method. All samples containing spikes at concentrations of 2x LOD ₉₅ and LOD ₉₅ shall show a positive result with Microsart® ATMP Bacteria. | method; see Appendix) |
|--|---|---|-----------------------|

| | Microsart® ATMP Bacteria | | | Compendial culture method (External) | | |
|-------------------------------|--------------------------|-------------------|----------------------|--------------------------------------|----------------------|----------------------|
| | 2x LOD ₉₅ | LOD ₉₅ | LOD ₉₅ /2 | 2x LOD ₉₅ | LOD ₉₅ | LOD ₉₅ /2 |
| <i>Bacillus subtilis</i> | 33.16 33.23 | 34.23 34.32 | 35.47 34.38 | <i>B. subtilis</i> | <i>B. subtilis</i> | <i>B. subtilis</i> |
| <i>Staphylococcus aureus</i> | 35.42 34.13 | 35.77 35.67 | 36.56 39.90 | <i>S. aureus</i> | <i>S. aureus</i> | <i>S. aureus</i> |
| <i>Clostridium sporogenes</i> | 34.20 34.10 | 34.87 33.43 | 35.45 35.61 | <i>C. sporogenes</i> | <i>C. sporogenes</i> | <i>C. sporogenes</i> |
| <i>Pseudomonas aeruginosa</i> | 36.40 36.22 | 36.74 37.96 | 37.22 No Cq | <i>P. aeruginosa</i> | <i>P. aeruginosa</i> | Negative |
| <i>Streptococcus pyogenes</i> | 34.89 35.09 | 35.53 35.93 | 36.55 35.88 | <i>S. pyogenes</i> | <i>S. pyogenes</i> | <i>S. pyogenes</i> |
| <i>Pseudomonas protegens</i> | 34.14 33.28 | 34.38 34.51 | 36.52 35.61 | Gram – Oxidase + | Gram – Oxidase + | Gram – Oxidase + |

7.3 Robustness

7.3.1 Cell culture samples spiked with bacteria

| Link | Procedure | Acceptance Criterion | Results |
|------------------|--|--|---------|
| See Table 17A; 1 | Four samples containing different cell lines in a relevant cell density and in typical cell culture media were spiked with 99 CFU/ml of <i>Bacillus subtilis</i> . | All spiked samples shall show a positive result. | Passed |

7.3.2 Device

| | <i>Bacillus subtilis</i> 99 CFU (FAM™) | | | |
|---------------|--|-------|--------------------------|-------|
| | 10 ⁶ cells/ml | | 10 ⁵ cells/ml | |
| Hela | 30.73 | 29.67 | 30.64 | 28.80 |
| | 30.49 | 28.46 | 29.16 | 29.50 |
| | 4/4 | | 4/4 | |
| Vero | 30.46 | 29.78 | 30.95 | 29.07 |
| | 30.96 | 29.71 | 30.45 | 29.53 |
| | 4/4 | | 4/4 | |
| CHO-K1 | 30.29 | 29.31 | 30.03 | 29.30 |
| | 29.81 | 29.42 | 30.40 | 28.73 |
| | 4/4 | | 4/4 | |
| RK13 | 30.75 | 29.82 | 31.04 | 29.25 |
| | 31.76 | 29.94 | 30.38 | 29.69 |
| | 4/4 | | 4/4 | |

compatibility


| Link | Procedure | Acceptance Criterion | Results |
|--------------------------------------|---|---|---------|
| See Table 17A; 2 See Table 17B; 6 | As the test can basically be performed with any qPCR cyclers capable of interpreting FAM™ and ROX™ signals, performance of the test with these machines needs to be validated. As not all qPCR cyclers commercially available are | All samples shall show a positive result. | Passed |

accessible for validation, the following four devices representing block and air heating systems are tested: Rotor-Gene 6000, Mx3005p, CFX96 touch and ABI Prism 7500. The robustness of the method was demonstrated by spiking DMEM + 5 % FBS with 99 CFU/ml of *Clostridium sporogenes*. At least eight replicates shall be tested on each instrument.


Rotor-Gene 6000 (Microsart® ATMP Bacteria)

| Extract | C _q (FAM™) | | C _q (ROX™) | | Result |
|-------------------------------|-----------------------|-------------------|-----------------------|-------|----------|
| | Run 1 | Run 2 | Run 1 | Run 2 | |
| Positive Control | 23.06 | 28.07 | 26.96 | 27.43 | Correct |
| Positive Control | 22.65 | 28.22 | 26.50 | 27.28 | Correct |
| NTC | No C _q | No C _q | 27.72 | 27.90 | Correct |
| NTC | No C _q | No C _q | 28.10 | 27.83 | Correct |
| NEC | No C _q | No C _q | 27.97 | 28.04 | Correct |
| NEC | No C _q | No C _q | 27.73 | 27.68 | Correct |
| <i>Clostridium sporogenes</i> | 31.86 | 30.81 | 27.05 | 27.54 | Positive |
| | 33.28 | 30.49 | 27.90 | 27.16 | Positive |
| | 33.41 | 31.83 | 27.76 | 27.92 | Positive |
| | 32.87 | 31.56 | 27.65 | 27.91 | Positive |
| | 31.59 | 31.17 | 27.37 | 27.40 | Positive |
| | 33.18 | 30.63 | 27.81 | 27.27 | Positive |
| | 33.06 | 31.60 | 27.37 | 27.81 | Positive |
| | 33.27 | 32.01 | 27.65 | 27.80 | Positive |

C. sporogenes 99 CFU Extracts (FAM™) (Rotor-Gene 6000)




C. sporogenes 99 CFU Extracts (ROX™) (Rotor-Gene 6000)




Mx3005p (Microsart® ATMP Bacteria)

| Extract | C _q (FAM™) | | C _q (ROX™) | | Result |
|-------------------------------|-----------------------|-------------------|-----------------------|-------|----------|
| | Run 1 | Run 2 | Run 1 | Run 2 | |
| Positive Control | 22.63 | 24.15 | 33.55 | 31.64 | Correct |
| Positive Control | 24.96 | 24.79 | 32.93 | 31.68 | Correct |
| NTC | No C _q | No C _q | 33.16 | 32.18 | Correct |
| NTC | No C _q | No C _q | 32.58 | 32.19 | Correct |
| NEC | No C _q | No C _q | 33.26 | 31.71 | Correct |
| NEC | No C _q | No C _q | 33.06 | 32.04 | Correct |
| <i>Clostridium sporogenes</i> | 32.02 | 32.64 | 33.32 | 32.34 | Positive |
| | 32.20 | 32.27 | 32.76 | 31.94 | Positive |
| | 31.70 | 31.64 | 33.97 | 31.79 | Positive |
| | 32.39 | 31.70 | 33.58 | 31.37 | Positive |
| | 31.81 | 32.62 | 33.26 | 32.14 | Positive |
| | 32.52 | 32.97 | 33.78 | 32.28 | Positive |
| | 32.13 | 32.70 | 32.89 | 31.98 | Positive |
| | 31.87 | 33.17 | 33.08 | 32.38 | Positive |
| | 32.07 | 32.73 | 33.73 | 32.03 | Positive |
| | 32.04 | 32.81 | 32.67 | 32.14 | Positive |

C. sporogenes 99 CFU Extracts (FAM™) (Mx3005p)




C. sporogenes 99 CFU Extracts (ROX™) (Mx3005p)




CFX96 (Microsart® ATMP Bacteria)

| Extract | C _q (FAM™) | | C _q (ROX™) | | Result |
|-------------------------------|-----------------------|-------------------|-----------------------|-------|----------|
| | Run 1 | Run 2 | Run 1 | Run 2 | |
| Positive Control | 24.01 | 23.86 | 30.36 | 28.53 | Correct |
| Positive Control | 24.19 | 24.00 | 30.30 | 28.33 | Correct |
| NTC | No C _q | No C _q | 33.19 | 29.37 | Correct |
| NTC | No C _q | No C _q | 33.31 | 29.58 | Correct |
| NEC | No C _q | No C _q | 32.13 | 29.3 | Correct |
| NEC | No C _q | No C _q | 32.86 | 29.85 | Correct |
| <i>Clostridium sporogenes</i> | 33.78 | 33.09 | 30.91 | 29.16 | Positive |
| | 33.61 | 35.03 | 30.81 | 28.84 | Positive |
| | 33.80 | 34.38 | 30.92 | 28.78 | Positive |
| | 34.07 | 33.94 | 31.26 | 28.85 | Positive |
| | 34.08 | 34.08 | 31.08 | 29.21 | Positive |
| | 34.48 | 34.47 | 31.09 | 29.65 | Positive |
| | 34.71 | 38.50 | 30.86 | 28.92 | Positive |
| | 34.12 | 34.09 | 31.25 | 29.14 | Positive |
| | 34.45 | 33.60 | 30.8 | 28.86 | Positive |
| | 34.27 | 33.70 | 31.21 | 28.75 | Positive |

C. sporogenes 99 CFU Extracts (FAM™) (CFX96)




C. sporogenes 99 CFU Extracts (ROX™) (CFX96)




ABI Prism (Microsart® ATMP Bacteria)

| Extract | C _q (FAM™) | | C _q (ROX™) | | Result |
|-------------------------------|-----------------------|-------------------|-----------------------|-------|----------|
| | Run 1 | Run 2 | Run 1 | Run 2 | |
| Positive Control | 25.14 | 24.66 | 33.63 | 35.06 | Correct |
| Positive Control | 25.96 | 25.88 | 34.20 | 31.89 | Correct |
| NTC | No C _q | No C _q | 34.44 | 32.96 | Correct |
| NTC | No C _q | No C _q | 34.37 | 32.48 | Correct |
| NEC | No C _q | No C _q | 33.91 | 32.23 | Correct |
| NEC | No C _q | No C _q | 33.62 | 32.94 | Correct |
| <i>Clostridium sporogenes</i> | 31.40 | 34.38 | 30.64 | 31.64 | Positive |
| | 32.40 | 33.92 | 33.19 | 31.24 | Positive |
| | 33.48 | 33.37 | 34.45 | 31.12 | Positive |
| | 32.77 | 33.49 | 32.56 | 31.90 | Positive |
| | 32.88 | 36.06 | 34.02 | 31.54 | Positive |
| | 32.37 | 34.42 | 33.10 | 31.91 | Positive |
| | 33.42 | 33.11 | 33.09 | 30.93 | Positive |
| | 33.91 | 33.26 | 33.44 | 30.76 | Positive |
| | 34.07 | 37.22 | 32.59 | 33.52 | Positive |
| | 35.02 | 34.94 | 36.19 | 32.00 | Positive |

C. sporogenes 99 CFU Extracts (FAM™) (ABI)



C. sporogenes 99 CFU Extracts (ROX™) (ABI)



7.3.2 Detection of Free-DNA

| Link | Procedure | Acceptance Criterion | Results |
|------------------------|---|----------------------|---|
| See Table 17A; 3 and 4 | In order to estimate the risk of false positive, water with and without cell suspension was spiked with 10 ⁴ ; 10 ³ ; 10 ² or 10 GC/ml <i>Escherichia coli</i> . The samples were divided in eight aliquots, extracted with Microsart® ATMP Extraction and tested with Microsart® ATMP Bacteria. | n.a | Without cell lines in the sample, more than 99% of the free DNA is eliminated during the extraction process. With cell lines in the sample, more than 90% of the free DNA is eliminated during the extraction process. |

| | 10 ⁴ GC/ml | | 10 ³ GC/ml | | 10 ² GC/ml | | 10 GC/ml | | 0 GC/ml | |
|---------------------------------|---|-------------------|---|-------------------|--|-------------------|------------------------------|-------------------|-------------------|-------------------|
| | Run 1 | Run 2 | Run 1 | Run 2 | Run 1 | Run 2 | Run 1 | Run 2 | Run 1 | Run 2 |
| Extracts without cells | 39.00 | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q |
| | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q |
| | 39.93 | 39.89 | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q |
| | 39.38 | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q |
| | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q |
| | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q |
| | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q |
| | 10⁴ GC/ml = 10² GC/PCR | | 10³ GC/ml = 10 GC/PCR | | 10² GC/ml = 1 GC/PCR | | 10 GC/ml = 0,1 GC/PCR | | 0 GC/PCR | |
| | Run 1 | Run 2 | Run 1 | Run 2 | Run 1 | Run 2 | Run 1 | Run 2 | Run 1 | Run 2 |
| Direct PCR without cells | 31.37 | 31.97 | 35.57 | 35.01 | No C _q | 38.11 | No C _q | No C _q | No C _q | No C _q |
| | 31.29 | 31.28 | 35.14 | 35.02 | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q |

After extraction 10³ GC/ml, 10 µl extract contain less than 1GC.
 Thus, more than 99% free DNA was washed away during the extraction process.

| | 10 ⁴ GC/ml | | 10 ³ GC/ml | | 10 ² GC/ml | | 10 GC/ml | | 0 GC/ml | |
|---------------------------------|---|-------------------|---|-------------------|--|-------------------|------------------------------|-------------------|-------------------|-------------------|
| | Run 1 | Run 2 | Run 1 | Run 2 | Run 1 | Run 2 | Run 1 | Run 2 | Run 1 | Run 2 |
| Extracts with cells | No C _q | 38.14 | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q |
| | 36.92 | 35.43 | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q |
| | 38.08 | 35.21 | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q |
| | 39.68 | 37.18 | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q |
| | 35.84 | 35.62 | No C _q | 35.49 | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q |
| | 35.44 | 35.84 | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q |
| | 36.54 | No C _q | 34.56 | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q |
| | 36.00 | 36.79 | 36.20 | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q |
| | 10⁴ GC/ml = 10² GC/PCR | | 10³ GC/ml = 10 GC/PCR | | 10² GC/ml = 1 GC/PCR | | 10 GC/ml = 0,1 GC/PCR | | 0 GC/PCR | |
| | Run 1 | Run 2 | Run 1 | Run 2 | Run 1 | Run 2 | Run 1 | Run 2 | Run 1 | Run 2 |
| Direct PCR without cells | 32.78 | 34.80 | 34.93 | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q | No C _q |
| | 32.49 | 34.81 | 36.31 | No C _q | 38.76 | No C _q | No C _q | No C _q | No C _q | No C _q |


After extraction 10² GC/ml with cell lines, 10 µl extract contain less than 1GC.
 Thus, more than 90% free DNA was washed away during the extraction process.

7.3.3 False positive rate

| Link | Procedure | Acceptance Criterion | Results |
|------------------------------------|---|----------------------|--|
| See Table 2 See Table 17A; 5 | Cell culture Media without spike were extracted with Microsart® ATMP Extraction and tested with Microsart® ATMP Bacteria. 12 independent experiments were performed for DMEM + 5%FCS, each with eight replicates. For other culture media, one experiment was performed, with eight replicates. | n.a | All the run conducted with Microsart® Bacteria Extraction and Microsart® ATMP Bacteria were valid indicating that none of those media affect the performance of the kit. |

| | Negative Results | % negative results |
|---------------|------------------|--------------------|
| DMEM + 5% FCS | 8/8 | 98,95% |
| | 8/8 | |
| | 8/8 | |
| | 8/8 | |
| | 8/8 | |
| | 7/8 | |
| | 8/8 | |
| | 8/8 | |
| | 8/8 | |
| | 8/8 | |
| | 8/8 | |
| | 8/8 | |

| | Negative Results | ROX™ | % negative results |
|---|------------------|-------------|--------------------|
| DMEM | 8/8 | 8/8 Correct | 100% |
| DMEM high Glucose, GlutaMAX | 8/8 | 8/8 Correct | 100% |
| RPMI 1640 | 8/8 | 8/8 Correct | 100% |
| RPMI 1640, GlutaMAX | 8/8 | 8/8 Correct | 100% |
| MEM (1) | 8/8 | 8/8 Correct | 100% |
| MEM (2) | 8/8 | 8/8 Correct | 100% |
| KnockOut DMEM | 7/8 | 8/8 Correct | 87.5% |
| DMEM/F-12 GlutaMAX | 8/8 | 8/8 Correct | 100% |
| Opti-MEM Reduced Serum GlutaMAX | 8/8 | 8/8 Correct | 100% |
| McCoy's 5A Medium | 8/8 | 8/8 Correct | 100% |
| Leibovitz L-15 Medium | 8/8 | 8/8 Correct | 100% |
| Chondrocyte Differentiation Medium | 8/8 | 8/8 Correct | 100% |
| Human Osteoblast Differentiation Medium | 7/8 | 8/8 Correct | 87.5% |
| Mesencult ACF Basal Medium | 8/8 | 8/8 Correct | 100% |
| Mesencult ACF Basal Medium + Mesencult ACF Supplement | 8/8 | 8/8 Correct | 100% |
| ChondroMAX Differentiation Medium | 8/8 | 8/8 Correct | 100% |
| StemPro Osteo/Chond Dif Basal + StemPro Chondrogenesis Supplement | 8/8 | 8/8 Correct | 100% |
| StemPro Osteo/Chond Dif Basal + StemPro Osteogenesis Supplement | 8/8 | 8/8 Correct | 100% |

| | | |
|--|--|---|
|  | Product Validation Report Microsart® ATMP Bacteria/ Microsart® ATMP Sterile Release | Dated: 04.12.2019 Document Version: 2 Document ID: VA06.01EN Page 35 of 40 |
|--|--|---|

8 Conclusion

Microsart® ATMP Bacteria and the Bacteria SR Mix from Microsart® ATMP Sterile Release were intensively validated in compliance with the designed validation protocol. The validation protocol reflects the method itself and variations expected by the diversity of samples from different customers during QC testing in the manufacturing process of ATMP samples. Microsart® ATMP Bacteria should be applied for Bacteria detection for any kind of sample material occurring in the manufacturing process of ATMP.

Microsart® ATMP Bacteria and its derivate product Microsart® ATMP Sterile Release were designed as state-of-the-art new product for the detection of bacterial contaminations in ATMP products. The products validation has been conducted according to the *European Pharmacopoeia* 2.6.1 and 2.6.27 regulations for sterility testing and microbiological control of cellular products such as ATMP. The study provided detailed information about the performance of the kit regarding:

- all bacteria species that are requested by the EP 2.6.1 and 2.6.27
- the influence of samples matrices frequently used for manufacturing ATMPs and cell culture in general
- the influence of common lab to lab alternative sample preparation techniques

Specificity of the tested bacteria revealed a detection limit (LOD₉₅) comprised between 2.5 and 99 CFU/ml and a great sensitivity of the PCR system, able to detect as little as 10 GC/PCR for various species.

In silico sequence alignments analysis demonstrated that Microsart® ATMP Bacteria and Microsart® ATMP Sterile Release can detect > 94 % of Gram positive and Gram negative bacteria. This feature greatly increase the chances to detect any kind of bacterial contamination, including some species difficult to detect with the classical culture method. A direct comparison with the culture method recommended by EP 2.6.1 was performed and showed 100% of similarities between the results obtained through both methods.

As robustness is a key issue in evaluating the characteristics of a product, the kit has been validated with various relevant samples, with standard cell culture material and with different PCR cyclers using the kits as directed. All collected results are consistent and confirm the accuracy and reproducibility of Microsart® ATMP Bacteria and Microsart® ATMP Sterile Release in those diverse surroundings for the detection of bacterial DNA.

It was shown that the products Microsart® ATMP Bacteria and Microsart® ATMP Sterile Release offers an alternative to the requirements of EP 2.6.1 and EP 2.6.27 and can be safely used to detect the presence of bacterial contamination in cell culture derived samples including ATMPs.

9 Reference Documents

1. T. Montag et al., Bundesgesundheitsbl 2010, 53:45–51: Probleme der mikrobiellen Sicherheit bei neuartigen Therapien
2. European Pharmacopoeia 8th edition, Strasbourg, FR; European Directorate for the Quality of Medicines; 2014, 5.1.6
3. US Pharmacopoeial Convention (USP). USP 38/NF 33 <1223>, 2015
4. Paul Ehrlich Institut: Stellungnahme zur mikrobiologischen Kontrolle von hämatopoietischen Stammzellzubereitungen, URL: http://www.pei.de/SharedDocs/Downloads/blut/stammzellen-genehmigung-21a-amg/pei-stellungnahme-mikrobiologische-kontrolle-stammzellen.pdf?__blob=publicationFile&v=3, 02.06.2015
5. European Pharmacopoeia 8th edition, Strasbourg, FR; European Directorate for the Quality of Medicines; 2015; 2.6.27 Microbiological examination of cell based preparations

10 Appendix



1. Prüfungsdurchführung

1.1 Prüfung auf Sterilität

Die Prüfungen wurden am 23.05.2018 mittels Direktbeschickung unter einer qualifizierten Sicherheitswerkbank (LS SWB 024) durchgeführt.

Hierbei wurde jeweils der Gesamthalt pro Gebinde in einen 400 ml Kolben Nährmedium überführt. Gemäß Kundenvorgaben wurden die Proben mit der Bezeichnung „a“ in 400 ml Thio-Bouillon überführt. Die Proben mit der Bezeichnung „b“ wurden in 400 ml Caso-Bouillon überführt.

1.2 Inkubation

Nach der Prüfungsdurchführung wurden die Testansätze bei $22,5 \pm 2,5$ °C (Caso-Bouillon, KL 023) bzw. $32,5 \pm 2,5$ °C (Thio-Bouillon, KL 022) in einer qualifizierten Klimakammer mit kontinuierlicher Temperaturlaufzeichnung inkubiert.

1.3 Auswertung und Resultate

Alle Testansätze wurden arbeitstäglich auf makroskopisch sichtbares Wachstum überprüft. Nach 6 Tagen (am 29.05.2018) Inkubationszeit, wiesen die ersten Ansätze eine visuelle Trübung auf. Die geforderte Inkubationszeit von 14 Tagen wurde somit vorzeitig aufgrund der Ergebnisse der visuellen Auswertung beendet. Bei diesen Testansätzen erfolgte unmittelbar die Anlage einer Subkultur mit nachfolgender Identifizierung.

Alle weiteren Testansätze wurden weiterhin bis zum Ende der 14-tägigen Inkubationszeit inkubiert und arbeitstäglich auf makroskopisch sichtbares Wachstum überprüft. Die Endauswertung erfolgte im 4-Augen-Prinzip.

Alle Resultate der visuellen Auswertung sowie der Identifizierung sind der *Tabelle 1: Übersichtstabelle aller Testansätze* zu entnehmen.

Die Zuordnung der LS-Nummern der Sterilitätsprüfung zu den entsprechenden LS-Nummern der Identifizierung wird in *Tabelle 2: Zuordnung LS-Nummern Sterilität und Identifizierung* dargestellt.

Tabelle 1: Übersichtstabelle aller Testansätze

| LS-Nr.: | Produkt-name | Bezeichnung | Sterilität* | betroffene Nährmedien | Ergebnis Identifizierung |
|-----------------|---------------|-------------|-------------|-----------------------|--------------------------|
| 180523-0197-001 | DMEM + 5% FCS | 1 a | E | Thio | - |
| | | 1 b | E | Caso | - |
| 180523-0197-002 | DMEM + 5% FCS | 2 a | EN | Thio | Bacillus subtilis group |
| | | 2 b | EN | Caso | Bacillus subtilis group |
| 180523-0197-002 | DMEM + 5% FCS | 3 a | EN | Thio | Bacillus subtilis group |
| | | 3 b | EN | Caso | Bacillus subtilis group |
| 180523-0197-004 | DMEM + 5% FCS | 4 a | EN | Thio | Bacillus subtilis group |
| | | 4 b | EN | Caso | Bacillus subtilis group |
| 180523-0197-005 | DMEM + 5% FCS | 5 a | E | Thio | - |
| | | 5 b | E | Caso | - |
| 180523-0197-006 | DMEM + 5% FCS | 6 a | EN | Thio | Staphylococcus aureus |
| | | 6 b | EN | Caso | Staphylococcus aureus |
| 180523-0197-007 | DMEM + 5% FCS | 7 a | EN | Thio | Staphylococcus aureus |
| | | 7 b | EN | Caso | Staphylococcus aureus |
| 180523-0197-008 | DMEM + 5% FCS | 8 a | EN | Thio | Staphylococcus aureus |
| | | 8 b | EN | Caso | Staphylococcus aureus |
| 180523-0197-009 | DMEM + 5% FCS | 9 a | E | Thio | - |
| | | 9 b | E | Caso | - |
| 180523-0197-010 | DMEM + 5% FCS | 10 a | EN | Thio | Clostridium sporogenes |
| | | 10 b | EN | Caso | Clostridium sporogenes |
| 180523-0197-011 | DMEM + 5% FCS | 11 a | EN | Thio | Clostridium sporogenes |
| | | 11 b | E | Caso | - |
| 180523-0197-012 | DMEM + 5% FCS | 12 a | EN | Thio | Clostridium sporogenes |
| | | 12 b | E | Caso | - |
| 180523-0197-013 | DMEM + 5% FCS | 13 a | E | Thio | - |
| | | 13 b | E | Caso | - |
| 180523-0197-014 | DMEM + 5% FCS | 14 a | E | Thio | - |
| | | 14 b | E | Caso | - |
| 180523-0197-015 | DMEM + 5% FCS | 15 a | EN | Thio | Pseudomonas aeruginosa |
| | | 15 b | EN | Caso | Pseudomonas aeruginosa |
| 180523-0197-016 | DMEM + 5% FCS | 16 a | EN | Thio | Pseudomonas aeruginosa |
| | | 16 b | EN | Caso | Pseudomonas aeruginosa |
| 180523-0197-017 | DMEM + 5% FCS | 17 a | E | Thio | - |
| | | 17 b | E | Caso | - |
| 180523-0197-018 | DMEM + 5% FCS | 18 a | EN | Thio | Streptococcus pyogenes |
| | | 18 b | EN | Caso | Streptococcus pyogenes |
| 180523-0197-019 | DMEM + 5% FCS | 19 a | EN | Thio | Streptococcus pyogenes |
| | | 19 b | EN | Caso | Streptococcus pyogenes |
| 180523-0197-020 | DMEM + 5% FCS | 20 a | EN | Thio | Streptococcus pyogenes |
| | | 20 b | EN | Caso | Streptococcus pyogenes |

Bericht über Resultate der Prüfung auf Sterilität

Produktbezeichnung: DMEM + 5% FCS
 LS-Nr.: 180523-0197-001 bis 024

Version: 01
 Seite: 3 von 5



| LS-Nr.: | Produkt-name | Bezeichnung | Sterilität* | betroffene Nährmedien | Ergebnis Identifizierung |
|-----------------|---------------|-------------|-------------|-----------------------|--|
| 180523-0197-021 | DMEM + 5% FCS | 21 a | E | Thio | - |
| | | 21 b | E | Caso | - |
| 180523-0197-022 | DMEM + 5% FCS | 22 a | E | Thio | - |
| | | 22 b | EN | Caso | gramnegative Stäbchen, Oxidase positiv |
| 180523-0197-023 | DMEM + 5% FCS | 23 a | E | Thio | gramnegative Stäbchen, Oxidase positiv |
| | | 23 b | EN | Caso | - |
| 180523-0197-024 | DMEM + 5% FCS | 24 a | E | Thio | - |
| | | 24 b | EN | Caso | gramnegative Stäbchen, Oxidase positiv |

* E: Entspricht, EN: Entspricht nicht

Tabelle 2: Zuordnung LS-Nummern Sterilität und Identifizierung

| LS-Nummern der Prüfung auf Sterilität | Zugehörige LS-Nummern der Identifizierung |
|---------------------------------------|---|
| 180523-0197-002 | 180523-0197-025 |
| 180523-0197-003 | 180523-0197-026 |
| 180523-0197-004 | 180523-0197-027 |
| 180523-0197-006 | 180523-0197-028 |
| 180523-0197-007 | 180523-0197-029 |
| 180523-0197-008 | 180523-0197-030 |
| 180523-0197-010 | 180523-0197-031 |
| 180523-0197-011 | 180523-0197-039 |
| 180523-0197-012 | 180523-0197-040 |
| 180523-0197-015 | 180523-0197-032 |
| 180523-0197-016 | 180523-0197-033 |
| 180523-0197-018 | 180523-0197-034 |
| 180523-0197-019 | 180523-0197-035 |
| 180523-0197-020 | 180523-0197-036 |
| 180523-0197-022 | 180523-0197-037 |
| 180523-0197-023 | 180523-0197-041 |
| 180523-0197-024 | 180523-0197-038 |

2. Wachstumskontrollen

2.1 Eingesetzte Testkeime

Bei LS Nr.: 180523-0197-001 wurden Wachstumskontrollen im Anschluss an die Sterilprüfung durchgeführt. Die Ergebnisse entsprechen den Anforderungen und sind dem Analysenzertifikat zu entnehmen.

| Unterschriften zur Autorisierung | | | |
|----------------------------------|----------|---------------------------------------|--|
| erstellt: | Labor LS | Sandra Räder (Fachleitung) | 2 5. JUNI 2018 (Datum/Unterschrift) |
| geprüft/ genehmigt: | Labor LS | Stefan Gärtner (Abteilungsleitung) | 2 5. JUNI 2018 (Datum/Unterschrift) |

Ende des Dokuments

Appendix of the Product Validation Report for Microsart® ATMP Bacteria

This technical note summarizes additional LOD₉₅ data (limit of detection) for bacterial species which have not been covered during product validation but are of relevance for kit users, which includes *Cutibacterium acnes* (ATCC 11827), *Serratia marcescens* (ATCC 14756) and *Peptostreptococcus anaerobius* (ATCC 27337).

| Link | Procedure | Acceptance Criterion | Results / LOD ₉₅ |
|---|---|--|--|
| See chapter 6.7.1 (LOD ₉₅ determination) of the Product Validation Report Microsart® ATMP Bacteria | CFU-quantified bacterial suspensions were diluted, according to their individual cell count, in DMEM to prepare suspensions with concentrations from 99 to 0 CFU/ml. Individual dilution series were prepared. Dilutions from 99 to 0 CFU/ml were tested according to the test procedure described in chapter 6.7.1 of the validation report. Only data of relevant concentrations for LOD ₉₅ determination are shown below. | The cut-off is defined as the lowest bacteria concentration [CFU/ml] which leads in 95 % of the tests to a positive result (here 16/16 and 8/8 samples have to be positive). LOD ₉₅ must be ≤ 99 CFU | Passed (LOD ₉₅ is between 25 CFU and 50 CFU) (And all control reactions fulfilled acceptance criteria) |

Serratia marcescens

| CFU/ml | | | | | | Mean | |
|--------|-------|-------|-------|-------|-------|-------|--------|
| 99 | Run 1 | 35,81 | 35,41 | 36,81 | 34,63 | 35,67 | 15/16* |
| | Run 2 | 35,30 | 34,12 | 34,27 | 35,47 | 34,79 | |
| | Run 3 | 33,98 | 34,20 | 34,75 | 34,06 | 34,25 | |
| | Run 4 | 32,05 | 32,94 | N/A* | 33,13 | 32,71 | |
| 50 | Run 1 | 37,08 | 35,00 | 35,39 | 34,98 | 35,61 | 16/16 |
| | Run 2 | 34,06 | 35,12 | 36,66 | 35,48 | 35,33 | |
| | Run 3 | 36,00 | 37,60 | 36,06 | 36,59 | 36,56 | |
| | Run 4 | 32,40 | 34,04 | 34,35 | 33,20 | 33,50 | |
| 10 | Run 1 | No Cq | No Cq | 37,92 | No Cq | 37,92 | 10/16 |
| | Run 2 | 37,05 | 38,57 | 38,96 | 36,38 | 37,74 | |
| | Run 3 | No Cq | 36,80 | No Cq | No Cq | 36,80 | |
| | Run 4 | 35,48 | 35,17 | 35,97 | 36,99 | 35,90 | |

Cutibacterium acnes

| CFU/ml | | | | | | Mean | |
|--------|-------|-------|-------|-------|-------|-------|------|
| 25 | Run 1 | 38,35 | 37,41 | 35,65 | 38,49 | 37,48 | 7/8* |
| | Run 2 | N/A* | 39,02 | 39,22 | 39,20 | 39,15 | |
| 10 | Run 1 | No Cq | 38,48 | 39,67 | No Cq | 39,08 | 6/8 |
| | Run 2 | 38,09 | 37,77 | 38,80 | 38,81 | 38,37 | |
| 5 | Run 1 | 39,10 | No Cq | No Cq | No Cq | 39,10 | 4/8 |
| | Run 2 | 39,02 | 37,26 | No Cq | 38,76 | 38,35 | |

*Two samples in total showed PCR inhibition most likely due to residual lysis buffer in the final DNA extract

2

Peptostreptococcus anaerobius

| CFU/ml | | | | | | Mean | |
|--------|-------|-------|-------|-------|-------|-------|-----|
| 50 | Run 1 | 34,99 | 36,08 | 34,31 | 38,39 | 35,94 | 8/8 |
| | Run 2 | 32,57 | 32,14 | 31,88 | 33,19 | 32,45 | |
| 25 | Run 1 | 36,93 | 36,05 | 36,02 | 36,61 | 36,40 | 8/8 |
| | Run 2 | 33,15 | 33,92 | 32,30 | 33,16 | 33,13 | |
| 10 | Run 1 | 38,67 | 37,93 | 36,42 | 38,34 | 37,84 | 8/8 |
| | Run 2 | 35,64 | 34,63 | 34,40 | 34,96 | 34,91 | |
| 5 | Run 1 | 38,76 | 38,72 | 38,23 | 37,75 | 38,37 | 8/8 |
| | Run 2 | 36,19 | 35,36 | 35,26 | 36,18 | 35,75 | |

| Species | LOD ₉₅ Summary |
|---|---------------------------|
| <i>Serratia marcesens</i> (ATCC 14756) | 50 CFU/ml |
| <i>Cutibacterium acnes</i> (ATCC 11827) | 25 CFU/ml |
| <i>Peptostreptococcus anaerobius</i> (ATCC 27337) | 5 CFU/ml |